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Apoptotic signals are tightly regulated in cells to prevent accidental or unwanted cell death. 
In cancer cells, however, multiple defects exist in the apoptotic machinery to evade programmed 
cell death. Commonly reported defects include the overexpression of anti-apoptotic proteins (e.g. 
Bcl-2, FLIP, survivin, or inhibitor of apoptotic proteins (IAPs)) or the downregulation of pro-
apoptotic proteins (e.g. death receptor or Apaf-1) to resist execution of apoptotic cell death by the 
executioner caspase (caspase-3). Paradoxically, the zymogen of the executioner caspase, 
procaspase-3, rather than being downregulated in cancer, has been found to be overexpressed in 
many cancers. In Chapter 1, I will describe the list of cancers that overexpress procaspase-3, before 
rationalizing this paradoxical observation. Finally, I will discuss emerging data from our 
laboratory in exploiting procaspase-3 overexpression as an anticancer strategy. In particular, I will 
outline the preclinical and clinical development of a selective procaspase-3 activating small 
molecule (PAC-1) as an anticancer therapy.  
Activation of an executioner caspase such as caspase-3 leads to cleavage of hundreds of 
proteins in the cell, leading eventually to apoptotic cell death. In Chapter 2, I will first discuss the 
proteomic identification of caspase-3 substrates in whole cells treated with pro-apoptotic agents. 
Interestingly, two of the identified substrates of caspase-3, MEK1 and MEK2, are critical 
gatekeeper kinases in the mitogen-activated protein kinase (MAPK) pathway. Next, I will discuss 
the prevalence of oncogenic drivers in the MAPK pathway and the development of inhibitors as 
targeted anticancer therapeutics. Finally, I will explore the prospects of caspase-mediated 
degradation of MEK1/2 kinases as a strategy to overcome resistance to targeted therapies that 
inhibit kinases along the MAPK pathway.   
One of the oncogenic driver mutations in the MAPK pathway is the V600E mutation on 
the BRAF protein. More than 50% of melanomas harbor this mutation that can be drugged with a 
BRAFV600E inhibitor vemurafenib. Chapter 3 reports the synergistic activity of PAC-1 + 
vemurafenib and PAC-1 + vemurafenib + trametinib in enhancing caspase-3 activity and apoptotic 
cell death in BRAFV600E melanoma cell lines.  As a result of increased caspase-3 activity and 
resultant MEK1/2 degradation, the PAC-1 + vemurafenib combination induces significant 
reduction in tumor volume in a murine xenograft model of BRAFV600E melanoma, beyond the 
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antitumor effects of the individual agents. In addition, the combination is also effective in 
significantly delaying the regrowth of cells after exposure to vemurafenib.  Finally, PAC-1 remains 
effective in vemurafenib-resistant A375VR cells in culture and synergizes with vemurafenib to 
retard tumor growth of these cells in vivo. 
In the MAPK pathway, kinases/GTPases upstream of the canonical effector kinase ERK1/2 
are frequently mutated or altered. The BRAFV600E mutation discussed in Chapter 3, is a well-
studied kinase that is mutated in the MAPK pathway. Besides BRAFV600E, EGFR, ALK, ABL, and 
RAS are oncogenes that are frequently altered in this pathway. While many mutant oncogenes 
have been identified, only mutations or alterations to EGFR, ALK, and ABL kinases can be 
targeted clinically by specific kinase inhibitions to elicit a therapeutic benefit. Chapter 4 describes 
my efforts to combine PAC-1 with kinase inhibitors targeting mutant EGFR, EML4-ALK, and 
BCR-ABL, to enhance apoptotic cell death and ultimately delay acquired resistance.  
Given that PAC-1 is currently in a Phase I clinical trial (NCT02355535), and the kinase 
inhibitors used in Chapters 3 and 4 are already approved by the FDA, the preclinical data results 
presented herein can inform the design of future trials to investigate novel PAC-1 combination 
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Chapter 1. Understanding procaspase-3 overexpression in cancers and implications for 
therapeutic intervention 
1.1. Introduction 
Apoptotic signals are tightly regulated in cells to prevent accidental or unwanted cell death. 
In cancer cells, however, multiple defects exist in the apoptotic machinery to evade programmed 
cell death. Commonly reported defects include the overexpression of anti-apoptotic proteins (e.g. 
Bcl-2, FLIP, survivin, or inhibitor of apoptotic proteins (IAPs)) or the downregulation of pro-
apoptotic proteins (e.g. death receptors or Apaf-1) to resist execution of apoptotic cell death by the 
executioner caspase (caspase-3). Paradoxically, the zymogen of the executioner caspase, 
procaspase-3, rather than being downregulated in cancer, has been found to be overexpressed in 
many cancers. In this chapter, I will describe the list of cancers that overexpress procaspase-3, 
provide possible explanations for this paradoxical observation, and finally discuss emerging data 
from our laboratory in exploiting procaspase-3 overexpression as an anticancer strategy. 
  
1.2. Blood, brain, and solid cancers that overexpress procaspase-3 
Overexpression of procaspase-3 has been reported in blood-derived cancers such as 
lymphoma,1-5 leukemia,3,6-9 and multiple myeloma10 via immunohistochemistry (IHC) of patient-
derived samples or western blotting (WB) of cell lines (Table 1.1). In our laboratory, we have also 
shown that dogs with spontaneously occurring lymphoma express higher levels of procaspase-3.11 
As in blood-derived cancers, common brain cancers such as glioblastoma,12-15 meningioma,16,17 
and neuroblastoma18 have higher levels of procaspase-3 as determined by IHC or WB (Table 1.1). 
Our laboratory has also confirmed that higher levels of procaspase-3 in glioblastoma correlates 
with shorter overall survival (OS).15  
Unlike in brain and blood-derived cancers where overexpression of procaspase-3 has been 
seen across major subtypes, reports regarding the overexpression of procaspase-3 in solid cancers 
have been more discordant (Table 1.1). In breast,19-23 melanoma,24,25 lung,26-29 colorectal,30-33 
esophageal,34,35 and stomach36 cancers higher levels of procaspase-3 have been consistently 
reported. Moreover, the observation that colorectal cancers overexpressed procaspase-3 was also 
confirmed in our laboratory.37 On the other hand, conflicting reports regarding the expression of 
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procaspase-3 have been reported in hepatocellular carcinomas (HCCs) and pancreatic cancers. In 
HCCs, differences in the detection methodology (IHC and WB in Rashid et al.38; in-situ 
hybridization in Hao et al.39; RT-PCR and IHC in Nakano et al40) and patient population might 
have contributed to the discrepancy. Disagreement in literature regarding procaspase-3 levels in 
pancreatic cancer can be attributed to differences in patient population and procaspase-3 antibody 
used (rabbit polyclonal in Shimosegawa et al.41 and Soini et al.42 versus rabbit monoclonal in 
Pryczynicz et al.43). Finally, in cancers of the prostate44-46 and cervix,47 lower levels of procaspase-
3, rather than overexpression, have been reported. 
While overexpression of procaspase-3 appears to be near ubiquitous in blood-derived, 
brain, and most solid cancers, the prognostic value of this observation has been mixed (Table 1.1). 
In most cancers, overexpression of procaspase-3 does not seem to correlate with OS or 
progression-free survival (PFS).  
Table 1.1. List of cancers with reported procaspase-3 levels relative to normal tissue and clinical prognosis. ALL = 
acute lymphocytic leukemia; AML = acute myelogenous leukemia; CLL = chronic lymphocytic leukemia; NHL = 
non-Hodgkin’s lymphoma; DLBCL = Diffuse large B cell lymphoma BL/BLL = Burkitt’s lymphoma/Burkitt-like 
lymphoma; NSCLC = non-small cell lung cancer; CR = complete remission; N.D. = not determined 










 Chaber et al.1  
 
 Pääkko et al.2 
 Reed et al.3 
 Ohshima et al.4 
 Pringle et al.5  
Overexpressed 
 












 AML and 
ALL 
 
 Reed et al.3 
 Kornblau et al.6 
 Gandhi et al.7 
 Estrov et al.8 
 




 Shorter OS 
 N.D 
 More CR, no difference in 
OS 
 Not statistically different 
Multiple 
myeloma 
 Gandhi et al.10 Overexpressed  N.D. 
Brain 
Glioblastoma 
 Kaiser et al.12 
 Carlotti Jr. et al.13 
 Murphy et al.14 




 Longer PFS 
 Shorter OS 
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Table 1.1 (cont.) 
Meningioma 
 Patsouris et al.16  
 Vranic, A.17  Overexpressed 
 Higher grade and shorter PFS 
 Higher grade; no difference 
in PFS or OS 
Neuroblastoma  Sakiyama et al.18 Overexpressed  Lower grade and longer OS 
Solid Tumor 
Breast 
 Zapata et al.19 
 Krajewski et al.20 
 Grigoriev et al.21 
 O’Donovan et al.22 






 Shorter OS 
Melanoma 
 Zhou et al.24  
 Jansen et al.25 
Overexpressed 
 No correlation with survival  
 N.D. 
Lung (NSCLC) 
 Selinger et al.26 
 Paakko et al.27 
 Wada et al.28  




 Shorter OS 
 N.D. 
Colorectal 
 Prehn et al.30  
 
 Prehn et al.31   
                       
 Kedra et al.32 
 Nicholson et al.33 
 Putt et al.37  
Overexpressed 
 No difference in OS in Stage 
II and III 
 Longer PFS and OS in Stage 





 Wang et al.34 
 Hu et al.35 
 
Overexpressed 
 Longer OS 
 Longer OS in primary tumor; 
shorter OS in lymph node 
mets 
Gastric  Konturek et al.36 Overexpressed  N.D. 
Hepatocellular 
 Rashid et al.38 
 Hao et al.39 
 Nakano et al.40 
 Overexpressed  
 Under-expressed 
 Under-expressed 
 No correlation with OS 
 No correlation with OS 
 N.D. 
Pancreatic 
 Shimosegawa et al.41 
 
 Soini et al.42 





 Similar levels 
 Cytoplasmic procaspase-3 
correlates with increased 
invasiveness 
 N.D. 
 No correlation  
Prostate 
 Watson et al.44  
 Royuela et al.45 





 Shorter PFS  
 N.D. 
Cervical  Wang et al.47 Under-expressed  N.D. 
 
1.3. Why is procaspase-3 overexpressed in most cancers? 
Regardless of the utility of procaspase-3 levels in predicting disease outcome, there is 
compelling evidence demonstrating its overexpression in a wide variety of cancers. The 
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observation that procaspase-3 is overexpressed rather than downregulated is paradoxical 
considering its role in the apoptotic machinery. Here, I discuss five hypotheses to explain the 
overexpression of procaspase-3 in cancer cells.  
1.3.1. Dysregulation of CASP3 transcription 
CASP3 (the gene encoding procaspase-3) was found to be one of the target genes for the 
E2F family of transcription factors.48 In the absence of growth signals, E2F forms a complex with 
the retinoblastoma (Rb) family of proteins, specifically pRb,49 which silences its transcriptional 
activity. When growth signals are present, CDK4/6 kinase is not inhibited by P16INK4a, and forms 
a complex with Cyclin D1 to phosphorylate pRb. Phosphorylated pRb then dissociates from the 
pRb-E2F complex, allowing E2F to regain its transcriptional activity (Fig. 1.1A). However, the 
Rb/E2F pathway is often dysregulated in many cancers, leading to unfettered transcriptional 
activity of E2F.50,51 
 
Figure 1.1. The pRb/E2F pathway in regulating transcription and cell cycle progression. (A) In the absence of growth 
signals, the transcriptional activity of E2F is inhibited through binding with pRb. (B) In cancer cells, loss of function 
of the CDKN2A gene or pRb, and less frequently the overexpression of CDK4/6 lead to relief of E2F inhibition by 
pRb, resulting in unregulated transcription.  
 
First discovered in inherited retinoblastoma, loss of function of pRb is found in numerous 
cancers (Fig. 1.2).50,52 Not surprisingly, one of the most common alterations to the Rb/E2F 
pathway in cancers is the mutation or loss of function of pRb. The loss of Rb relieves the inhibition 
on E2F, leading to uncontrolled transcription of downstream genes including CASP3 (Fig. 1.1B). 






















function mutation53 or inactivation of the CDKN2A gene54 which encodes it (Fig. 1.1B), also 
disrupts the inhibition on E2F. It should be noted that CDKN2A deletion is extremely prevalent 
and occurs in approximately 20% of all cancers (Fig. 1.3). Less common than loss of Rb and 
P16INK4a, overexpression of CDK4 and CDK651 have also been observed in tumor samples with 
dysregulated Rb/E2F pathway (Fig. 1.1B), though at lower frequency (Figs. 1.4 and 1.5). Taken 
together, the common occurrence of pRb/E2F pathway dysregulation in multiple cancers, which 
funnels to the eventual upregulation of CASP3 transcription, may prove to be a possible 
explanation for the prevalence of procaspase-3 overexpression across numerous cancers.  
 
Figure 1.2. Analysis of cancers with loss or mutation of the RB1 gene. All studies are from TCGA with the exception 
of SCLC, as reported by the cBio Portal (May 2017). SCLC = small cell lung cancer; Uterine CS = Uterine 
carcinosarcoma; GBM = glioblastoma multiforme; NSCLC = non-small cell lung cancer; ACC = Adrenocortical 
Carcinoma; DLBC = diffuse large B-cell lymphoma; chRCC = kidney chromophobe; PCPG = pheochromocytoma 


























































































































































































































Figure 1.3. Analysis of cancers with loss or mutation of the CDKN2A gene. All studies are from TCGA with the 
exception of MPNST, as reported by the cBio Portal (May 2017). MPNST = malignant peripheral nerve sheath tumor; 
AML = acute myeloid leukemia; refer to Figure 1.2 for legend of the remaining abbreviations.  
 
 
Figure 1.4. Analysis of cancers with overexpression of CDK6. All studies are from TCGA, as reported by the cBio 






















































































































































































































































































































































































































































































































































Figure 1.5. Analysis of cancers with overexpression of CDK4. All studies are from TCGA, as reported by the cBio 
Portal (May 2017). Refer to Figure 1.2 for legend regarding the abbreviations.  
 
1.3.2. Caspase-3 induced cell proliferation during apoptosis 
 While the notion of caspase-3 mediated apoptosis leading to cell proliferation is 
counterintuitive, there are well-documented examples in numerous organisms to support this 
idea.55 First observed in Drosophila melanogaster, apoptotic cells as a result of injury or stress, 
were found to stimulate the production of pro-growth mitogens such as Wg (Drosophila orthologue 
of human WNT) and Dpp (Drosophila orthologue of human TGFβ) to stimulate cell proliferation 
via the Wnt pathway.56-59 Later work found that apoptosis-induced cell proliferation was also 
observed in lower organisms such as Hydra spp., Planaria, newts, Xenopus tadpoles, and 
zebrafish.55 A similar phenomenon was also observed in mammals. Li and co-workers found that 
mice deficient in caspase-3 (Casp3-/-) needed a longer time for wounds to heal.60 In addition, 
Casp3-/- mice also required a longer period of time for their liver to regenerate following an 
injury.60 In both cases, they found that caspase-3 cleavage of calcium-independent phospholipase 
A2 (iPLA2) stimulates the production of arachidonic acid and PGE2, to promote cell proliferation 
via the Wnt pathway. Therefore, there is evidence to suggest that dying cells with active caspase-

















































































































































































































 Moving beyond studies in lower organisms and mice, elegant work by Li and co-workers 
has also shown that caspase-3 activation in apoptotic breast cancer cells also leads to the cleavage 
of iPLA2, and increased secretion of arachidonic acid and PGE2
 (Fig. 1.6).61 This result was not 
observed in CASP3-/- breast cancer cells. The activation of the iPLA2–arachidonic acid–PGE2 
pathway, and subsequently the WNT pathway, promotes the compensatory proliferation of 
CASP3+/+ breast cancer cells following radiation therapy. Moreover, secretion of PGE2 in 
chemotherapy-induced apoptotic bladder cancer cells was also reported to promote tumor 
repopulation and cancer stem cell proliferation.62 The release of PGE2 by apoptotic cells might 
also explain the intriguing observation that mixing viable cancer cells with dying ones further 
enhances cell proliferation.63 Sub-lethal activation of caspase-3 in ovarian cancer cells also 
activates iPLA2–arachidonic acid signaling, not to promote proliferation but rather cell 
migration.64  
The data presented herein suggests that caspase-3 activation promotes the secretion of pro-
growth factors such as PGE2 to promote proliferation and survival of cancer cells. As a zymogen, 
procaspase-3 possesses significantly lower catalytic activity compared to caspase-3.65-67 
Therefore, overexpression of procaspase-3 in cancer cells might be a compensatory mechanism to 
elevate overall caspase-3 activity, so as to promote tumor persistence in the presence of 
environmental stress. In this way, the higher basal expression of procaspase-3 likely provides a 
survival advantage for cancer cells, possibly accounting for its paradoxical overexpression in 
cancer.   
 




1.3.3. Caspase-3 induced angiogenesis  
  Besides its role in promoting cell proliferation, caspase-3 activation has also been shown 
to promote angiogenesis. In rats with severe pulmonary hypertension, pulmonary endothelial cell 
apoptosis is often accompanied by the development of intravascular pulmonary endothelial cell 
growth.68 Moreover, treatment of the endothelial cells with a pan-caspase inhibitor prevented the 
formation of intravascular pulmonary endothelial cell, suggesting that dying pulmonary 
endothelial cells promote the growth of blood vessels near the sites of death.68 In another study, 
Voelkel and co-workers demonstrated that phagocytosis of apoptotic Jurkat cells by macrophages 
or endothelial cells promotes the secretion of VEGF-A and growth of endothelial cells.69 A major 
limitation of the two studies is the lack of control experiments in cells that do not express caspase-
3 or lack caspase-3 activity, making it difficult to ascribe a causal relationship between caspase-3 
activity and angiogenesis.   
Recent work by Huang and co-workers have demonstrated that radiation-induced apoptosis 
in glioma70 and colorectal71 cancer cells also led to VEGF-A secretion and angiogenesis. In both 
cases, glioma or colorectal cells expressing catalytically active caspase-3 led to increased secretion 
of VEGF-A and blood vessel formation, compared to the corresponding cells expressing 
catalytically dead caspase-3 (C163A). In dying glioma cells expressing catalytically competent 
caspase-3, PGE2 secretion is also elevated, further contributing to angiogenesis.
70 It is unclear why 
dying colorectal cancer cells, unlike dying glioma cells, do not secrete PGE2. While the studies 
support the role of caspase-3 activation in promoting angiogenesis, the mechanism of how that 
happens remains poorly understood. In dying colorectal cancer cells, Huang and co-workers 
postulated that caspase-3 activity enhances the phosphorylation of AKT, thereby increasing the 
production of VEGF-A.71 No further explanation was provided to explain how caspase-3 activity 
influences AKT activity. In the case of dying glioma cells, the authors invoke that caspase-3 
activation triggered the induction of COX-2 and phosphorylation of eIF4E to release PGE2 and 
VEGF-A respectively, to promote angiogenesis.70  
Due to the low catalytic activity of procaspase-3, overexpression is likely necessary to 
elevate the overall level of caspase-3 activity present in cancer cells. In light of the data presented 
herein, elevated levels of caspase-3 activity is beneficial in promoting VEGF-A secretion and 
blood vessels formation, both of which are required to support the rapid expansion of cancer cells. 
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Consequently, overexpression of procaspase-3 likely serves to improve the “fitness” of cancer 
cells during tumor growth and colonization.  
1.3.4. Caspase-3 induced DNA damage and genetic instability 
Proteins involved in DNA repair were found to be preferentially cleaved by caspase-3 
during apoptosis.72 Reports by Li and co-workers73,74 and Tait and co-workers75 have implicated 
that sub-lethal activation of caspase-3 led to widespread DNA damage, genetic instability, and 
oncogenesis.  
In the first study, Li and co-workers used sub-lethal doses of ionizing radiation to 
demonstrate that breast cancer cells lacking procaspase-3 expression or lacking catalytically 
competent caspase-3, were less likely to harbor genetic aberrations compared to cells with 
procaspase-3 expression.73 In addition, tumor formation in nude mice was also compromised when 
breast cancer cells do no express procaspase-3 or have inactive caspase-3. In the second study, 
they found that sub-lethal activation of caspase-3 (in the absence of radiation or 
chemotherapeutics) promotes DNA damage and Myc-induced oncogenesis in breast epithelial 
cells (MCF10A). Using CRISPR/Cas9 to remove the expression of procaspase-3 in MCF10A cells 
significantly reduced DNA damage and Myc-induced oncogenic transformation. MCF10A cells 
lacking procaspase-3 form less colonies in soft agar assays and do not form tumors in nude mice.74 
In both studies, they found that the DNA damage was mainly mediated by endonuclease G 
(EndoG), a DNase that is released from the mitochondria, following caspase-3 activation (Fig. 
1.7), since knocking out EndoG inhibited DNA damage in procaspase-3 expressing cells.73,74 It 
should be noted, however, that EndoG activity has been shown to be activated even when caspase-
3 activity is inhibited with a pan-caspase inhibitor,76 indicating that caspase-3 activation may not 
be entirely responsible for EndoG-mediated DNA damage.  
In a separate report by Tait and co-workers, they found that sub-lethal concentrations of 
the pro-apoptotic Bcl-2/Bcl-xl inhibitor ABT-737 led to minority mitochondria outer membrane 
permeablization (MOMP), and extensive caspase-3-mediated DNA damage.75 Treatment with a 
pan-caspase inhibitor abolishes extensive DNA damage, reduces the transformation of 
immortalized fibroblast cells, and inhibits tumor formation in nude mice.75 In MCF7 cells that lack 
procaspase-3 expression, negligible levels of DNA damage were detected when treated with ABT-
737, and overexpression of procaspase-3 in MCF7 cells resulted in extensive DNA damage. In this 
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study, it was found that sub-lethal level of caspase-3 activation led to cleavage of caspase-activated 
DNase (also known as DNA fragmentation factor), triggering its DNA fragmenting activity (Fig. 
1.7).75 Taken together, caspase-3-mediated activation of DNase activity was observed in cancer 
cells when exposed to sub-lethal levels of environmental stress, thereby promoting DNA damage 
and oncogenic transformation.  
Although procaspase-3 possesses weak catalytic activity, the data presented herein 
suggests that elevated procaspase-3 expression could provide sub-lethal caspase-3 activity, which 
might be sufficient to promote DNA damage and oncogenesis. Hence, cells that overexpress 
procaspase-3 are likely to be more susceptible to caspase-induced DNA damage and genetic 
instability, promoting their transformation to cancer cells.  
 
Figure 1.7. Sub-lethal activation of caspase-3 activity leads to active CAD or EndoG activity that drives DNA 





1.3.5. Post-translational modifications (PTMs) that inhibit caspase-3 activity 
 Caspase-3 is a cysteine protease with the catalytic residue at Cys163. S-nitrosylation on 
Cys163 has been reported to deactivate caspase-3 activity resulting in the inhibition of apoptosis 
in cancer and normal cells.77-79 Besides S-nitrosylation, glutathionylation of cysteine residues 
found in caspase-3 was also reported to inhibit its activity and induction of apoptosis.80 Finally, 
phosphorylation of Ser150 by p38-MAPK is also known to deactivate caspase-3 activity in 
neutrophils81 but little is known about its significance in inhibiting apoptosis in cancer cells. 
Therefore, the overexpression of procaspase-3 could be an attempt of last resort by cancer cells to 
counteract the inhibitory PTMs found on caspase-3, as an effort to promote apoptosis in these 
diseased cells.  
 
1.4. Targeting procaspase-3 overexpression as an anticancer therapy 
 One of the holy grails of anticancer drug research is to develop therapeutic agents that 
target a specific defect in cancer but not normal cells. Such agents would kill cancer cells 
selectively over normal cells, minimizing the toxic side effects that are commonly associated with 
chemotherapy. The ubiquity of procaspase-3 overexpression in cancer, therefore, presents us with 
a unique opportunity to target it selectively as an anticancer therapy. The following sections 
describe efforts from our lab to develop small molecules that promote the selective activation of 
procaspase-3 as a personalized anticancer strategy.   
1.4.1. Development of procaspase-3 activating compound (PAC-1) as an anticancer therapy 
 Recognizing that procaspase-3 is overexpressed in many cancers, the Hergenrother 
laboratory developed the first small molecule (PAC-1, Fig. 1.8) that is capable of selectively 
activating procaspase-3 to caspase-3.37 Extensive mechanistic and structure-activity relationship 
(SAR) studies have elucidated the importance of the ortho-hydroxy-N-acylhydrazone moiety in 
chelating the labile pool of inhibitory zinc ions bound to procaspase-3, thereby facilitating its auto-
activation to caspase-3.82,83 In cell culture, 72 h IC50 values of PAC-1 in multiple blood, brain, and 
solid cancer cell lines were found to be between 1 and 15 μM, but >100 μM in normal cells,84 
highlighting the selectivity of PAC-1 for cancer versus normal cells. In vivo, PAC-1 has shown 
single-agent efficacy in multiple xenograft and syngeneic murine models of cancer.15,37,85-87 
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Because of its unique mode of action, PAC-1 has been shown to synergize with diverse 
chemotherapeutics in multiple types of cancer.15,87-89 Cell culture studies, together with mouse 
models of cancer, have demonstrated significantly enhanced anticancer effect compared to single 
agents alone.15,87  
 
Figure 1.8. Structure of PAC-1, the ortho-hydroxy-N-acylhydrazone moiety is highlighted in blue.  
 
1.4.2. Evaluation of PAC-1 monotherapy and combination therapies in companion animals 
with spontaneously occurring tumors 
 Murine models of cancer, while useful in evaluating the anticancer efficacy of lead 
compounds, do not accurately recapitulate the de novo formation of tumors nor the 
intratumoral/intertumoral heterogeneity present in human cancer.90 These limitations, along with 
several others, have precluded the ability of mouse models to predict the efficacy of anticancer 
compounds in human patients. It was even argued that the rampant use of mouse models of cancer 
in preclinical testing is partly responsible for the high attrition of lead anticancer compounds in 
human clinical trials.90  In an effort to better translate preclinical efficacy to success in the clinic, 
our laboratory in collaboration with Prof. Tim Fan, has begun evaluating PAC-1 both as a single-
agent and in combination therapies in companion animals with spontaneously occurring tumors. 
In particular, canine cancers are genetically similar to the corresponding human malignancies,91 
making them good models to evaluate the safety and efficacy of PAC-1/PAC-1 combination 
therapies in animals with spontaneously occurring tumors.  
 In the first study, four dogs with lymphoma were treated with PAC-1 in combination with 
doxorubicin. In this cohort of canine patients, PAC-1 was orally administered at 75–100 mg/kg 
four hours prior to an IV dose of doxorubicin (30 mg/m2) on day 1 of the treatment cycle, and 
repeated every 14 days for three cycles. Following three treatment cycles, the combination regimen 
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was well-tolerated in all four dogs. Excitingly, two of the four dogs achieved complete response 
while the remaining two dogs had partial responses following the treatment (Table 1.2).87  
 
Table 1.2. PAC-1 and doxorubicin in dogs with lymphoma. Abbreviations: FS, female spayed; MC, male castrated; 
MI, male intact; PR, partial response; CR, complete response. 1PAC-1 was administered 4 h prior to treatment with 
doxorubicin. This treatment was repeated every 14 days, for three cycles. This table is adapted with permission from 
ACS Central Science Ref87 © (2016) American Chemical Society.   
     Treatment1  
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To evaluate the safety and efficacy of combining PAC-1 and doxorubicin in a more 
aggressive cancer, dogs with metastatic osteosarcoma (mOS) were treated with the combination. 
Retrospective analyses have shown that single-agent doxorubicin is minimally efficacious in 
reducing tumor burden in dogs with mOS,92,93 providing us with an excellent opportunity to 
evaluate the efficacy of PAC-1 + doxorubicin in this difficult to treat cancer. In this setting, six 
mOS dogs were either treated daily with 10.9–12.5 mg/kg of PAC-1 (metronomic) or once every 
14 days at a 50 mg/kg (high dose), with an IV dose of doxorubicin (20–30 mg/m2) on day 1 of the 
treatment cycle, and repeated every 14 days for three or more cycles. Three mOS dogs enrolled to 
receive the metronomic dosing regimen tolerated the treatment protocol, with two of the canine 
patients achieving partial responses following three cycles of treatment (Table 1.3).87 The high 
dose regimen was similarly well-tolerated in the remaining three mOS dogs that received the 
treatment protocol. In this case, biological response was only observed in one of the canine patients 
after nine treatment cycles (Table 1.4).87 Taken together, the combination of PAC-1 and 





Table 1.3. Metronomic PAC-1 and doxorubicin in dogs with mOS. Abbreviations: MC, male castrated; PD, 
progressive disease; PR, partial response. 1PAC-1 was administered daily for 6 weeks. Doxorubicin was given every 
14 days, for a total of 3 doses. This table is adapted with permission from ACS Central Science Ref87 © (2016) 
American Chemical Society.   
     Treatment1  
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Table 1.4. High dose PAC-1 and doxorubicin in dogs with mOS. Abbreviation: FS, female spayed; MC, male 
castrated; PD, progressive disease; SD, stable disease; PR, partial response.1PAC-1was administered 4 h prior to 
treatment with doxorubicin. This treatment was repeated every 14 days, for ≥3 cycles. Patients 8 and 10 received three 
treatment cycles. Patient 9 received a total of nine cycles of PAC-1 + dox treatments. Treatments 4–9 occurred with 
the doxorubicin dosage given in the third treatment (20 mg/m2). This table is adapted with permission from ACS 
Central Science Ref87 © (2016) American Chemical Society.   
     Treatment1  






































Being blood-brain permeable,94 PAC-1 (7.5–12.5 mg/kg orally for 28 consecutive days) as 
a single agent showed modest anticancer effect in dogs with glioblastoma multiforme (GBM), a 
highly aggressive and deadly form of brain cancer (Fig. 1.9 and Table 1.5).15 In humans, GBM is 
clinically managed with surgical resection, ionizing radiation, and temozolomide (TMZ).95 To 
evaluate if we can combine PAC-1 safely with ionizing radiation and TMZ, we chose to study this 
combination in dogs with GBM. Canine GBM is highly similar to human GBM at the pathology 
and molecular level,96 making it an ideal animal model for our study. In the combination study, 
PAC-1 (7.5–12.5 mg/kg) was dosed daily for 84 consecutive days, with ionizing radiation (3 
Gy/fraction, 16 fractions from days 29 to 51) and 100 mg/m2 of TMZ orally (10 days, days 29 to 
33 and days 57 to 61). All three dogs tolerated the 84-day treatment with no serious adverse events. 
Very excitingly, one of the dogs achieved a complete response (Fig. 1.9) while the remaining two 
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dogs achieved partial responses at the end of the study (Table 1.5).15 Collectively, these studies 
demonstrate that PAC-1 can be combined safely with the standard-of-care and elicit clinically 
meaningful responses in dogs with GBM. These results pave the way for the translation of PAC-1 
into the clinic for treatment of human malignancies.  
 
Figure 1.9. Brain MRI of patient 1 28 days post PAC-1 therapy and at the end of the 84-day treatment regimen. This 
figure is adapted with permission from Oncotarget Ref15 © (2017) Impact Journals.   
 
Table 1.5. Reduction in tumor volume following treatment with PAC-1, ionizing radiation, and TMZ for 84 days. 
Abbreviation: FS; spayed female. aPAC-1 dosage was 12.5 mg/kg for days 1-56, then reduced to 8.0 mg/kg for days 
57–84. This table is adapted with permission from Oncotarget Ref15 © (2017) Impact Journals.   
    
Change in Tumor Burden Following 
Treatment 












FS 7 12.5a 
↓ 6% ↓ 100% 
2 Dachshund FS 8 10.0 
↓ 5% ↓ 43% 
3 Boxer FS 5 7.5 
↑ 19% ↓ 60% 
 
1.4.3. Phase I clinical trial of PAC-1 in human cancer patients 
 Based on extensive preclinical data demonstrating the efficacy of PAC-1 both as a single 
agent and in combination with doxorubicin or TMZ, Vanquish Oncology has begun evaluating the 




























(NCT02355535). At the time of writing, 5 doses of PAC-1 have been evaluated in human patients: 
75 mg, 150 mg, 250 mg, 375 mg, and 450 mg, with higher doses being planned till the maximum 
tolerated dose was reached. All evaluable patients tolerated the drug well and no severe adverse 
events were reported. Despite the short half-life (t1/2) of PAC-1 in mice (~25 mins)
97 and dogs 
(~2.1 h)98, the t1/2 in humans at the 75 mg dose is significantly prolonged to ~24 hours. The 
prolonged t1/2 can be explained by the difference in metabolism between rodents and humans. In 
rats, PAC-1 was shown to be metabolized via oxidative N-debenzylation, olefin oxidation, and 
arene oxidation (Fig. 1.10).99 However, debenzylated PAC-1 was not observed in the serum of 
human cancer patients, indicating that the lack of oxidative N-debenzylation significantly 
improves its t1/2 in humans. 
 
Figure 1.10. Metabolism of PAC-1 in rats. In humans, oxidative N-debenzylation of PAC-1 was not observed. 
 
As a result of the prolonged t1/2 of PAC-1, satisfactory systemic exposure of PAC-1 was 
observed. At 24 h post oral administration of PAC-1, steady-state (trough) concentration of up to 
1.4 μM can be detected. Encouragingly, the trough levels seem to be proportional to dose, 
increasing from ~0.2 μM at the 75 mg to ~1.2 μM at the 450 mg dose (Fig. 1.11). More importantly, 
accumulation of PAC-1 was observed during the 21 day dosing regimen. Following 11 (75 mg 






administration, trough levels continue to scale with increasing dosages, and up to 5.4 μM can be 
achieved in a patient receiving 450 mg of PAC-1 for 21 days (Fig. 1.12). 
 
Figure 1.11. Trough levels of PAC-1 in human cancer patients 24 h post oral administration.  
 
 
Figure 1.12. Trough levels of PAC-1 in human cancer patients following 11 or 21 days of daily PAC-1 administration.  
 
The observation that ~2–3 μM of PAC-1 (Fig. 1.12) can be readily achieved in the serum 
of human cancer patients has important clinical implications. Extensive PK and 























































values of the targeted anticancer agent generally predict in vivo efficacy of targeted anticancer 
therapies._ENREF_100100 Given that the IC50 values of PAC-1 in multiple blood, brain, and solid 
cancer cell lines are between 1 and 15 μM,84 and that the trough levels of PAC-1 are proportional 
to dose, we are optimistic that sufficiently high concentrations of PAC-1 can be achieved in 
humans as we continue the dose escalation studies to observe anticancer efficacy.  
 
1.5. Summary and outlook 
 In this chapter, I have identified an extensive list of blood-derived, brain, and solid tumor 
cancers that overexpress procaspase-3. The observation that procaspase-3 is overexpressed rather 
than downregulated is paradoxical considering its role as an executioner caspase in the apoptotic 
machinery. One of the mechanisms for procaspase-3 overexpression might be the upregulation of 
CASP3 transcription due to the dysregulation of the pRb/E2F pathway in numerous cancers. Data 
from various laboratories have also pointed to the non-apoptotic role of caspase-3 in promoting 
tumor persistence following apoptosis, angiogenesis, and oncogenesis. These non-apoptotic roles 
of caspase-3 might have conferred cancer cells a selective survival advantage during the process 
of cancer development, and therefore explain the ubiquity of procaspase-3 overexpression in 
cancers. Finally, the presence of PTMs that inhibit the activity of caspase-3, might be a trigger for 
cancer cells to overexpress procaspase-3, in a futile attempt to override these inhibitory signals so 
as to execute programmed cell death.  
 The observation that procaspase-3 is overexpressed in numerous cancer has initiated a drug 
discovery program in the Hergenrother laboratory to develop a small molecule (PAC-1) that can 
selectively activate procaspase-3 in cancer cells. We and others have shown that single-agent PAC-
1 is effective in inducing apoptosis in a variety of cancer cell lines and exerts significant antitumor 
effect in vivo. More excitingly, the preclinical success of combining PAC-1 with TMZ and ionizing 
radiation in the management of canine GBM, has led to an early-stage clinical trial investigating 
this combination in human patients with recurrent GBM. With prolonged t1/2 and favorable 
systemic exposure of PAC-1 in human patients, we remain optimistic that single-agent PAC-1 or 
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Chapter 2. Caspase-3 activation and targeted anticancer therapies  
2.1. Introduction 
 In the previous chapter, I discussed the prevalence of procaspase-3 overexpression in a 
variety of cancers and small molecule activators of procaspase-3, such as PAC-1, as anticancer 
therapeutics. Activation of an executioner caspase, such as caspase-3, leads to the cleavage of 
hundreds of proteins in the cell, eventually leading to apoptotic cell death. In this chapter, I will 
first discuss the proteomic identification of caspase-3 substrates in whole cells treated with pro-
apoptotic agents. Interestingly, two of the identified substrates of caspase-3, MEK1 and MEK2, 
are critical gatekeeper kinases in the mitogen-activated protein kinase (MAPK) pathway. Next, I 
will discuss the prevalence of oncogenic drivers in the MAPK pathway and the prospects of 
caspase-3-mediated degradation of MEK1/2 kinases as a strategy to overcome resistance to 
targeted therapies that inhibit kinases along the MAPK pathway.   
  
2.2. Identification of caspase-3 substrates in cells by unbiased proteomics 
 Multiple gel-based and N-terminal peptide identification methods have been developed to 
investigate the sequence specificity and substrate scope of caspase-3 in cells.1,2 In a typical 
experiment, cells are first treated with a pro-apoptotic agent to induce caspase-3 activity, before 
lysing the cells for further analysis. In gel-based methods, lysates from treated and untreated 
samples are typically run on a 2D SDS-PAGE gel to resolve cleaved proteins from native proteins, 
before in-gel trypsin digestion and identification of caspase-3 substrates by LC/MS/MS. Gel-based 
methods, unlike the N-terminal peptide identification methods, do not have an enrichment step to 
select for proteins that have been cleaved by caspase-3 prior to LC/MS/MS analysis. The 
enrichment of cleaved proteins enhances the signal-to-noise ratio which can be beneficial in 
identifying low abundant caspase-3 substrates. Direct identification of substrate cleavage sites is 
also challenging for gel-based methods since the enrichment step is omitted from the workflow.  
The unique nature of the N-termini of proteins has been exploited to enrich for caspase-
cleaved substrates. The majority (~85%) of native proteins have their N-termini acetylated, and 
thus do not possess free α-amines.3 Since the majority of uncleaved proteins do not have free α 
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amines,3 caspase-cleaved substrates with non-acetylated N-termini provides a handle for 
researchers to selectively enrich for them versus native proteins.1,2 
2.2.1 Subtiligase-based enrichment of caspase-3 cleaved proteins 
 An enzymatic method developed by the Wells laboratory uses an engineered subtiligase 
enzyme to site-specifically modify caspase-cleaved proteins in etoposide-treated Jurkat cells with 
a biotinylated TEV peptide (Fig. 2.1A).4 The subtiligase enzyme has been engineered to react 
exclusively with α amines versus the more abundant ε amines found on lysine residues.5,6 
Following trypsin digest, the presence of biotinylated TEV peptide on caspase-cleaved peptides 
allows for positive enrichment using streptavidin beads (Fig. 2.1B). Finally, cleavage of the TEV 
peptide reveals SY-bearing N-terminal peptides which are subjected to LC/MS/MS analysis (Fig. 
2.1B). The characteristic mass of these peptides is useful in distinguishing caspase-cleaved 




Figure 2.1. Proteomics workflow developed by the Wells laboratory to identify caspase-3 substrates. (A) Engineered 
subtiligase selectively modifies caspase-cleaved proteins but not native proteins. (B) The modification of caspase-
cleaved proteins with a biotinylated TEV peptide allows the labeled proteins to be selectively enriched using 
streptavidin beads. Following TEV cleavage, the characteristic SY-bearing N-terminal peptides allow for unbiased 
identification of caspase substrates using LC/MS/MS.  
 
Using this methodology, 333 caspase-3 cleavage sites and 292 substrates were identified, 
including 240 new substrates that had not been previously reported in the CASBAH database.7  
One interesting finding from this work is that the in vitro substrate specificity of caspase-3 varies 
considerably from cellular cleavage sites. The canonical DEVD motif is found in <1% of cellular 
cleavage sites while the DXXD motif is only found in 22% of cleaved peptides.4 It turns out that 
the solvent accessibility of the cleavage site, in addition to its secondary structure (loop > α-helix 
> β-sheet), play important roles in determining where the protein is cleaved by caspase-3.4 This 
data highlights that caution should be exercised in predicting sites of caspase-3 cleavage using 
only the primary sequence of the protein. Second, it was found that caspase-3 tends to cleave 
multiple protein substrates that are part of a protein complex or a signaling pathway. In particular, 
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proteins involved in the inhibition of apoptosis and regulation of DNA repair/transcription tend to 
be cleaved by caspase-3 during apoptosis.4 This finding suggests that the activity of caspase-3 is 
not indiscriminate but specific towards proteins or protein complexes that regulate the key 
biochemical processes in the cell, highlighting the need to study caspase-3 activity in 
physiologically relevant conditions.  
 The subtiligase method developed by the Wells lab provides insights into the specificity of 
caspase-3 cleavage, but little information regarding the rate of caspase-3 cleavage, since only one 
cell line is evaluated using one proapoptotic agent at one timepoint. A modified methodology 
incorporating iTRAQ-based quantification allows researchers to monitor the kinetics of cleavage 
of up to 470 protein substrates, in different cell lines, induced with a variety of pro-apoptotic 
agents.8,9 Because N-terminal enrichment is employed, only newly-formed peptides can be 
detected. Therefore, no information regarding the extent of cleavage of the parent protein can be 
obtained from these studies. This information, if available, would provide us with a more complete 
picture of proteolysis events that occur in an apoptotic cell. This is where gel-based methods that 
do not rely on N-termini enrichment can be useful in monitoring the extent of protein cleavage 
throughout the course of apoptotic cell death.  
2.2.2. Protein Topography and Migration Analysis Platform (PROTOMAP) 
 Developed by the Cravatt laboratory, PROTOMAP is a gel-based proteomics platform to 
interrogate the extent of proteolytic events in cells undergoing apoptosis. In this method, untreated 
or staurosporine (STS) treated Jurkat cells were lysed and ran on a SDS-PAGE gel, where cleaved 
and uncleaved proteins are separated by differences in molecular weight.10 The gel was then sliced 
into 20 equally sized bands, followed by trypsin digest to extract peptidic fragments for sequencing 
via LC/MS/MS.10 Peptides corresponding to each protein in the control (red) or apoptotic (blue) 
sample, were then bioinformatically mapped into a peptograph, which plots the peptides according 
to their position in the primary sequence (N- to C-terminus) and molecular weight (Fig. 2.2).10 In 
the peptograph, the spectral count of bands in the control and apoptotic samples were also 
quantified, to reflect the relative intensity of the parental protein vs cleaved fragments. Therefore, 
by examining the peptograph of each protein in both the control and apoptotic samples, one can 
infer the cleavage site and the extent of protein cleavage that has occurred during apoptosis. In 
addition, by varying the duration of STS treatment (2, 4, or 6 hour) in Jurkat cells, the authors were 
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also able to determine the relative stability of the cleaved fragments for each protein over the 
course of apoptotic cell death.  
 
Figure 2.2. Workflow of PROTOMAP developed by the Cravatt laboratory. By examining the peptograph of each 
protein, the extent of cleavage, and in some cases, the cleavage site can be determined.  
 
 Using PROTOMAP, Cravatt and coworkers identified 261 caspase substrates, including 
170 new substrates that had not been previously reported in the CASBAH database.10,11 As 
mentioned earlier, the use of gel-based method in studying caspase-3 cleavage has the advantage 
of being able to monitor the extent of cleavage and stability of cleaved fragments over time. To 
monitor the extent and kinetics of caspase-3 cleavage, the spectral counts of the parental protein 
band after STS treatment were quantified. Approximately 31% of the substrates were almost 
completely degraded by caspases (Class I: <20% of the spectral counts are for the parental protein), 
39% were moderately degraded (Class II: 20–80% of spectral counts), with the remaining 30% 
having minor degradation by caspase-3 (Class III: >80% of spectral counts).10 While the extent of 
cleavage seems to be evenly distributed between these three classes, a slightly higher proportion 
(52%) of proteins are degraded more rapidly (<50% spectral counts of parental protein at 4 h STS 
treatment) than slower degrading proteins (38%).10 More interestingly, the authors have identified 
that 35% of the cleaved proteins have stable persistent fragments (observed in all 3 timepoints), 
47% are of intermediate stability (observed in two consecutive timepoints), and 12% are 
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transiently stable (observed only at 1 timepoint).10 This finding is in contrary to the widely-held 
belief that cleaved fragments are unstable and rapidly degraded by the proteasome due to the N-
end rule.12 As described previously, the lack of N-termini enrichment limits the ability of 
PROTOMAP to explicitly identify caspase cleavage sites, except in special circumstances.  
2.2.3. MEK1 and MEK2 kinases are substrates of caspase-3 during apoptosis 
 Taken together, work by the Cravatt and Wells laboratories have provided a more 
comprehensive understanding of the various factors that dictate the sites and extent of caspase-3 
cleavage in cells undergoing apoptosis. Intriguingly, the protein substrates for caspase-3 tend to 
be found in protein complexes or signaling pathways that govern cell fate and survival. Two such 
substrates are MEK1 and MEK2 kinases.  
MEK1 was identified as a substrate for caspase-3 using both the subtiligase method4 and 
PROTOMAP10. However, PROTOMAP was unable to identify the cleavage sites on MEK1 due 
to the lack of N-termini enrichment. Using the subtiligase-based enrichment method, two cleavage 
sites were identified on MEK1. The two sites are PAPD16 and VEGD282 (Fig. 2.3).4 Note that none 
of the reported sites correspond to the canonical DEVD or DXXD motif that is commonly 
identified in in vitro cleavage experiments. Using PROTOMAP, Cravatt and co-workers found 
that MEK1 was moderately degraded (70% of spectral counts reported for parent protein after 6 
hour of STS treatment) and the cleavage rate was slow (>50% spectral counts of parent protein 
after 4 hour).10 Since the cleaved fragments were found in two consecutive timepoints following 
STS treatment (4 and 6 hour), they determined that the fragments were of intermediate stability.10  
On the other hand, MEK2 was only identified as a substrate of caspase-3 from 
PROTOMAP but not the subtiligase method. Fortunately, Cravatt and co-workers were able to 
identify the cleavage site on MEK2 to be PVVD286 in this particular protein (Fig. 2.3).10 In this 
case, the cellular cleavage site also does not correspond to the DXXD motif commonly reported 
in in vitro experiments. Similar to MEK1, they found that that MEK2 was moderately degraded 
and the cleavage rate was slow.10 Unlike MEK1, the cleavage fragment of MEK2 was transiently 




Figure 2.3. Cleavage sites and simplified functional domains on MEK1 and MEK2 kinases.  
 
In the canonical MAPK pathway, MEK1 and MEK2 kinases play critical roles in regulating 
the activity of effector ERK1/2 kinases (Fig. 2.4), suggesting that cleavage by caspase-3 might 
disrupt its function and signal transduction via this pathway.  
 
Figure 2.4. MEK1 and MEK2 kinases are critical gatekeepers for ERK1/2 kinases in the MAPK pathway. This figure 
is reproduced with permission from Nature Ref 13 © (2015) Macmillan Publishers Ltd.  
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  Intriguingly, cleavage of MEK1 and MEK2 occurs at Asp282 and 286 respectively of the 
proline-rich domain (PRD), where BRAF (kinase that phosphorylates MEK1/2) binds to activate 
MEK1/2 kinases.14 This observation suggests that cleavage likely interferes with the 
phosphorylation and activation of MEK1 and MEK2 kinases by upstream kinases, to shut down 
MAPK signaling. In support of this hypothesis, a crystal structure of MEK1 bound to BRAF 
reveals that Ile310 and Leu314 (Fig. 2.5A), found in the PRD, are key residues that mediate the 
interaction of MEK1 and BRAF.15 Mutation of either or both residues to glutamic acid, abolished 
binding and subsequently the phosphorylation of MEK1 (Fig. 2.5B).15 Inhibition of MEK1 activity 
shuts down MAPK signaling as seen in the lack of ERK1/2 phosphorylation (Fig. 2.5B).15 While 
a similar crystal structure for BRAF/MEK2 is not available, the high sequence (87.8% determined 
using EMBOSS Needle Protein Pair Alignment Tool) (Fig. 2.6) and functional homology13 (Fig. 
2.4) between the two kinases suggest that activation of MEK2 by BRAF is likely similar to MEK1. 
Therefore, it is possible that cleavage of MEK1 and MEK2 kinases at the PRD likely disrupts their 
binding and activation by BRAF, which affects downstream MAPK signaling. Finally, cleavage 
of MEK1 at Asp16 found in the docking domain (DD) is likely to disrupt binding of MEK1 to 
ERK1/2 substrates. Numerous studies have shown that deletion or mutation of DD from MEK1 
abolishes binding to ERK1/2 kinases, which ultimately inhibited MAPK activation.16-18 Taken 
together, caspase-3 cleavage of MEK kinases likely interferes with key interactions with BRAF to 
affect MEK activation and also disrupts binding with downstream ERK1/2, to ultimately inhibit 






Figure 2.5. Residues on MEK1 influence binding to BRAF. (A) Crystal structure of the BRAF-MEK1 complex. The 
Ile310 and Leu314 residues that influence binding of the complex are highlighted in red. (B) Mutation of Ile310, or 
Leu314, or both residues in tandem abolished phosphorylation of MEK1 thus shutting down ERK1/2 activation. This 
figure is adapted with permission from Cancer Cell Ref 15 © (2014) Elsevier.  
 
 
MEK1       294 GRPLSSYGMDSRPPMAI310FELL314DYIVNEPPPKLPSGVFSLEFQDFVNKCLI    343 
               |||:|.:||||||.|||  ||||  ||||||||||||:|||:.:||:||||||| 
MEK2       302 GRPVSGHGMDSRPAMAI318FELL322DYIVNEPPPKLPNGVFTPDFQEFVNKCLI    351 
 
Figure 2.6. Sequence alignment of MEK1 and MEK2 kinase. Residues Ile310 and Leu314 on MEK1 are highlighted 
in blue with the corresponding Ile318 and Leu322 on MEK2. Sequence alignment was calculated using the EMBOSS 
Needle program available from EMBL-EBI. The Needleman-Wunsch algorithm was used to find the optimum 
alignment (including gaps) of two sequences along their entire length.  
 
2.3. Targeting oncogene mutations as an anticancer strategy 
 Besides the ability to resist cell death, another key hallmark of cancer is the ability to 
sustain uncontrolled proliferation.19 Unlike normal tissues where growth is carefully regulated 
through the controlled production of growth signals, cancer cells are able to sustain chronic 
proliferation in the absence of growth signals. Growth factor independent proliferation can be 
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achieved via numerous adaptive mechanisms including overexpression of growth factor ligands 
(e.g. HGF, EGF),20 receptors (e.g. EGFR, HER2),21,22 mutation/alteration of oncogenic proteins 
(e.g. BRAF, RAS),23 or inactivation of tumor suppressors in order to sustain uncontrolled cell 
growth.23 In the subsequent sections, I will examine the role of somatic mutations and 
translocations in activating oncogenes and the development of specific inhibitors as targeted 
anticancer therapies.  
 2.3.1. Oncogene driver mutations and affected cancers 
 With advances in DNA sequencing, large-scale studies have been conducted to sequence 
the genome of various forms of cancer. Depending on the type of cancer, tens to thousands of 
genes were found to be mutated in any given tumor sample.23-25 Despite this large number, the 
majority of them are considered passenger mutations that do not contribute to oncogenesis and are 
simply products of clonal expansion.23  
On the other hand, mutations found on certain proteins that confer tumor cells a survival 
advantage relative to normal cells are called driver mutations. Driver mutations can occur on tumor 
suppressor genes or oncogenes. A striking feature of oncogene driver mutations is the high 
frequency of recurring mutations on the same amino acids (Fig. 2.7A). A widely accepted 
definition of an oncogene is any protein that has >20% of its recorded mutations occurring on the 
same amino acid and are a result of a single base substitution (missense mutation).23 Not 
surprisingly, oncogene driver mutations are commonly found in proteins, that when mutated lead 
to constitutive activation to drive uncontrolled proliferation. In contrast to oncogenes, mutations 
on tumor suppressor genes (TSG) tend to be a combination of missense or truncating mutations, 
since there are multiple ways to disrupt the function of a protein (Fig. 2.7B). To be classified as a 
TSG, >20% of recorded mutations have to be inactivating.23  Using the above guidelines to classify 
oncogenes and TSGs, a total of 125 driver mutations comprising of 54 oncogenes and 71 TSGs 
have been identified.23 Recent sequencing efforts have identified several new driver mutations in 




Figure 2.7. Driver mutations in cancer occur on oncogenes or TSGs. (A) Distribution of missense mutations on BRAF 
oncogene as annotated on COSMIC. (B) Frameshift, missense, or silent mutations on the TP53 TSG.32  
 
Looking exclusively at oncogenes, a third (18 out of 54) of all driver mutations occur on 
kinases. Of the 18 kinases harboring driver mutations, 15 are involved in only two pathways, the 
MAPK and PI3K/AKT signaling pathways (Table 2.1). While there are many oncogenic kinases, 
they tend to be found in a limited number of pathways that govern cell proliferation and survival, 
implying that mutation of one kinase in the pathway is sufficient to activate downstream signaling. 
The mutual exclusivity of driver mutations has been confirmed experimentally: for instance a 
tumor with BRAF mutation does not harbor an additional driver mutation in RAS.33 Since multiple 
driver mutations do not occur concurrently in a tumor, if one can successfully inhibit a mutant 
oncogene, tumor regression is likely be achieved. This principle forms the basis of drug discovery 




Table 2.1. Driver mutations are typically found in kinases that signal through the MAPK or PI3K/AKT pathways.  
Oncogene Pathway 
ABL1 PI3K, RAS 
AKT1 PI3K 
ALK PI3K, RAS 
BRAF RAS 
EGFR PI3K, RAS 
ERBB2 PI3K, RAS 
FGFR2 PI3K, RAS, STAT 
FGFR3 PI3K, RAS, STAT 




KIT PI3K, RAS, STAT 
MAP2K1 RAS 
MET PI3K, RAS 
PI3KCA PI3K 
PDGFRA PI3K, RAS 
RET PI3K, RAS 
 
In addition to missense mutations, another common mechanism for cancer cells to hyper-
activate oncogenes is via the formation of recurrent fusion proteins.34,35 Fusion proteins are 
typically the result of translocation of chromosomes to create a coding sequence consisting of 
coding sequences from two different genes. Similar to oncogene driver mutations, a significant 
proportion of fusion proteins found in cancer cells involve kinases, in particular receptor tyrosine 
kinases35 (RTKs) (e.g. ABL1, ALK, PDGFRB, and RET). Likewise, fusion kinases are also 
commonly found in the MAPK or PI3K/AKT pathways that govern cell proliferation and 
survival.34 In the same way, fusion kinases typically occur in a manner that is mutually exclusive 




2.3.2. Drugging oncogene driver mutation as a targeted anticancer therapy  
The idea of developing molecular-based therapeutics has been a long-sought goal since 
Paul Ehrlich first proposed the idea of “magic bullets” for cancer therapy.36 In contrast to 
chemotherapy that kills rapidly proliferating cancer and normal cells indiscriminatingly, these 
drugs will be selectively cytotoxic to cancer but not normal cells. The identification of oncogene 
driver mutations and recurrent fusion proteins, and the observation that they occur in mutual 
exclusivity, provided researchers with an unique opportunity to develop drugs that are specific for 
the molecular defects found in cancer cells.  
Recognizing that kinases account for a third of all reported oncogene driver mutations and 
the majority of fusion proteins in cancer, substantial effort has been made in developing mutant-
specific inhibitors to treat cancers harboring these alterations. In fact, of the 35 kinase inhibitors 
approved to date, 17 were developed to inhibit mutant kinases selectively over their wild-type 
variant (Table 2.2). Clinical response to these kinase inhibitors have been remarkable, often 
shrinking tumors in patients with advanced disease within weeks of therapy with minimal side 
effects compared to standard chemotherapy.37  
Table 2.2. List of oncogene driver mutations or fusions commonly found in a variety of cancers. The list of FDA-
approved kinase inhibitors include first-generation inhibitors and second- or third-generation inhibitors that are 
effective against resistant tumors. Ph+ AML = Philadelphia chromosome positive acute myelogenous leukemia; CRC 
= colorectal cancer; GIST = gastrointestinal stroma tumor.  
Oncogene Targetable Alteration(s) Cancer Approved inhibitors 




ALK EML4-ALK fusion NSCLC 
Crizotinib, Ceritinib, 
Alectinib, Brigatinib 






















2.3.3. Resistance to targeted therapy 
 Rapid onset of resistance limits the durability of response to targeted anticancer 
therapies.37-39 This is powerfully shown in a patient with metastatic BRAFV600E melanoma who 
relapsed following 23 weeks of BRAFi treatment (Fig. 2.8).40 This observation, while 
disappointing, is not entirely unexpected given that hundreds to thousands of passenger mutations 
exist is any given tumor sample. While passenger mutations do not confer cancer cells a survival 
advantage, secondary mutations that confer a resistant phenotype will ultimately be positively 
selected for during the course of drug treatment. This selection pressure leads to the repopulation 
of resistant tumor cells following tumor regression observed early on during the treatment (Figs. 
2.8B and C). Therefore, to circumvent the inevitable onset of resistance, combination therapies 
that target multiple defects present in cancer cells are likely to be needed to provide longer 
remissions in cancer patients.  
 
Fig. 2.8. Rapid emergence of BRAFi resistance in a 38-year-old man with metastatic BRAFV600E melanoma. (A) 
Tumor burden before BRAFi treatment, (B) response to BRAFi treatment after 15 weeks, and (C) emergence of 
BRAFi resistant tumors after 23 weeks of therapy. This figure is adapted with permission from Journal of Clinical 
Oncology Ref 40 © (2011) American Society of Clinical Oncology.   
 
 A successful example of prolonging remissions via combination therapy is the addition of 
MEK1/2 inhibitors to BRAFV600E inhibitors in the management of BRAFV600E melanomas. 
Resistance to BRAFV600E inhibitors in BRAFV600E melanomas is often observed within 6 months 
of therapy and caused by reactivation of the MAPK pathway.41-43 As explained earlier, MEK1/2 
kinases are key regulators of the MAPK pathway,13 therefore, by concomitantly inhibiting 
BRAFV600E and MEK1/2 kinases, more durable response to BRAFi + MEKi therapy has been 
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observed.44,45 Therefore, by understanding the pathway that BRAFV600E signals through, a rational 
combination therapy involving MEK1/2 inhibition was developed and approved by the FDA. The 
early success of BRAFi + MEKi has prompted researchers to explore the combination of MEKi in 
cancers driven by a variety of oncogenic kinases (see Table 2.2) that also signal through MAPK.46-
49 In fact, trials evaluating the combination of EGFRi + MEKi (e.g. NCT02025114, 
NCT02580708), EML4-ALKi + MEKi (e.g. NCT03087448, NCT03202940), and BCR-ABLi + 
MEKi (e.g. NCT02225574) are currently ongoing or have been investigated in the clinic.  
2.3.4. Paradoxical phosphorylation of MEK1/2 following MEKi  
 Addition of MEK1/2 inhibitors to treatment regimens is effective in inhibiting ERK1/2 
phosphorylation and thus prevents reactivation of MAPK signaling. ERK1/2 phosphorylation, in 
addition to promoting downstream pro-growth signaling, is necessary to inhibit the activity of 
BRAF (Fig. 2.9A).13 Sustained inhibition of ERK1/2 phosphorylation by MEKi, therefore, 
disrupts the negative feedback with BRAF, leading to activation of MEK1/2 (Fig. 2.9B).  
 
Figure 2.9. Feedback regulation of BRAF is dependent on ERK1/2 activity. (A) Phosphorylation of ERK1/2 inhibits 
BRAF activity via negative feedback regulation. (B) In the presence of a MEK1/2 inhibitor, ERK1/2 phosphorylation 
is inhibited, resulting in the loss of negative feedback with BRAF. This activates BRAF to phosphorylate MEK1/2, 
leading to the paradoxical activation of MEK1/2 during periods of sustained ERK1/2 inhibition.  
 
This observation is evident when treating HCT116 cells (KRAS mutation) with increasing 
concentrations of cobimetinib (approved MEK1/2 inhibitor) decreases the amount of ERK1/2 
phosphorylation but paradoxically activates MEK1/2 kinases (Fig. 2.10A).50 In light of this 
observation, “feedback busters” such as trametinib (approved MEK1/2 inhibitor) was developed 
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to minimize the rebound in MEK1/2 phosphorylation.13 Treatment of HCT116 cells with 
trametinib inhibits both MEK1/2 and ERK1/2 phosphorylation at shorter timepoints but promotes 
MEK1/2 phosphorylation when the incubation was extended to 72 hours (Fig. 2.10B).51 Rebound 
in MEK1/2 phosphorylation occurs as early as 24 hour post-treatment, indicating that MEK1/2 
inhibition is a transient effect (Fig. 2.10B).51  
 
Figure 2.10. Differential effect of MEK1/2 inhibitors on MEK1/2 phosphorylation in KRAS mutant HCT116 cells. 
(A) Activation of MEK1/2 phosphorylation with increasing concentrations of GDC-0973 (0.45–330 nM) following 
an overnight incubation. (B) Trametinib inhibits MEK1/2 phosphorylation after 6 hours of incubation but not at longer 
timepoints. Figure 2.9A is adapted with permission from Nature Ref50 © (2013) Macmillan Publishers Ltd. Figure 
2.9B is adapted with permission from Clinical Cancer Research Ref51 © (2011) American Association of Cancer 
Research.    
 
While both cobimetinib and trametinib have been approved for use in melanomas with 
BRAFV600E mutation,44,45 the differential effect of MEK1/2 inhibitors in cancers harboring 
different driver mutations (Fig. 2.10), suggests that caution should be exercised when using these 
inhibitors in combination therapies. Moreover, even with the development of “feedback busters” 
such as trametinib, its ability to minimize the paradoxical activation of MEK1/2 is relatively short-
lived, indicating the need to develop more potent inhibitors or strategies to inactivate MEK1/2 




2.4. Summary and outlook 
 The identification of oncogene driver mutations and exploitation of pathway addiction have 
led to the development of an effective combination therapy involving BRAFi + MEKi in 
BRAFV600E melanomas. While preclinical results thus far seem to suggest that EGFRi + MEKi, 
EML4-ALKi + MEKi, and BCR-ABLi + MEKi are effective in delaying resistance, it remains to 
be seen if the benefit would also be observed clinically.  
Current efforts in shutting down MEK1/2 activity relies heavily on specific MEK1/2 
inhibitors. However, small-molecule mediated inhibition of MEK1/2 activity is transient and is 
abrogated within 24 h of compound treatment.51,52 One way to achieve more permanent inhibition 
of MEK1/2 activity would be to degrade it enzymatically so as to inactivate it completely. 
Proteomics studies have revealed that caspase-3 cleaves MEK1 and MEK2 kinases,4,10 raising the 
possibility of exploiting caspase-3-mediated degradation of MEK1/2 as a strategy to inactivate it 
in a more durable manner. Durable inhibition of MEK1/2 activity should result in sustained 
inhibition of MAPK signaling, thereby prolonging the therapeutic response to MEK combination 
therapies.  
Subsequent chapters will explore the addition of PAC-1 to inhibitors that target oncogenic 
kinases as a strategy to enhance caspase-3 activity, so as to effect caspase-mediated degradation 
of MEK1/2 kinases and sustained inhibition of MAPK signaling. In addition, I will also explore if 
PAC-1 combination therapies with diverse kinase inhibitors is more effective in delaying acquired 
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Chapter 3. The combination of vemurafenib and PAC-1 is synergistic in BRAFV600E 
melanomas 
Portions of this chapter are reproduced with permission from literature (Peh, J.; Fan, T. M.; 
Wycislo, K. L.; Roth, H. S.; Hergenrother, P. J. The Combination of Vemurafenib and Procaspase-
3 Activation is Synergistic in Mutant BRAF Melanomas Mol. Cancer. Ther. 2016, 15, 1859-
1869.)1 or are submitted for publication.  
Animal experiments were performed in collaboration with Prof. Timothy M. Fan. 
Immunohistochemistry analysis was performed by Dr. Kathryn L. Wycislo. PAC-1 and PAC-1a 
were synthesized by Dr. Howard S. Roth.  
3.1. Introduction 
3.1.1. BRAFV600E melanomas, discovery of vemurafenib, and emergence of clinical resistance 
Melanoma is the most common cutaneous malignancy and upon metastasis is considered 
the deadliest form of skin cancer.2 Metastatic melanomas are notoriously chemo-resistant to major 
classes of chemotherapeutics (such as nitrosoureas, taxanes, vinca alkaloids, platinum-drugs, and 
DNA topoisomerase inhibitors); all these agents fail to provide survival benefit over dacarbazine 
in large randomized clinical trials.3 Dacarbazine, which until 2011 was the only FDA approved 
chemotherapeutic for metastatic melanoma, only marginally extends progression-free survival 
(PFS), with ~15% of patients benefitting based on a pooled analysis of 23 randomized trials.4  
To better understand the genomics and identify druggable targets found in melanoma, the 
Wellcome Trust sequenced over 40 melanoma samples and discovered the presence of BRAFV600E 
mutation in ~50% of the sequenced samples.5 Subsequent clinical reports also validated the 
prevalence of BRAFV600E mutation in melanomas.6 Unlike BRAFWT, which signals as a dimer 
upon activation by RAS, monomeric BRAFV600E is able to phosphorylate the downstream MEK1/2 
kinases, independent of RAS activation, to activate the MAPK pathway (Fig. 3.1A).7  This 
discovery spurred the development of BRAFV600E inhibitors,8,9 and the subsequent approval of 
vemurafenib in 2011. As a potent inhibitor of BRAFV600E, vemurafenib led to the downstream 
inhibition of ERK1/2 activity, and induces apoptotic cell death in BRAFV600E melanoma cells.8,10 
BRAFV600E inhibitors like vemurafenib (Fig. 3.2) lead to impressive reduction in tumor 
burden within weeks of therapy, and extension of PFS relative to dacarbazine.11,12 Despite their 
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initial activity, resistance to vemurafenib rapidly emerges. In the majority of resistant tumors, 
reactivation of the MAPK signaling pathway is observed (Fig. 3.1B).13 Given that MEK1/2 kinases 
are the ultimate gatekeeper kinases of the MAPK pathway,14 addition of a MEK1/2 inhibitor (e.g. 
trametinib, Fig. 3.2) to the treatment regimen for metastatic melanoma has been investigated and 
subsequently approved by the FDA. While BRAFi + MEKi therapy is effective in extending 
PFS,15,16 resistance invariably occurs due to secondary activating mutations on MEK1/2 (Fig. 
3.1C).17-20 Given the current clinical limitations of existing therapies, novel and rationally-
designed combination studies with other kinase inhibitors are being explored.21,22 Despite all 
efforts to date, the development of resistance to targeted BRAFV600E therapies emerges in virtually 
100% of patients treated; acquired resistance to vemurafenib remains a significant clinical 
problem. 
 
Figure 3.1. Role of BRAFV600E in melanoma oncogenesis and drug resistance mechanisms to reactivate MAPK 
signaling. (A) BRAFV600E signals as a monomer to activate MAPK. (B) Mechanisms of BRAFi resistance involve 
reactivation of MAPK through NRAS mutation, BRAF splice variant, or MEK mutations. (C) Resistance to BRAFi 
+ MEKi occurs due to RAS and MEK mutations.  
 
Figure 3.2. Structures of the BRAFV600E inhibitor vemurafenib and MEK1/2 inhibitor trametinib.  
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3.1.2. Novel combination of BRAFV600E inhibition and procaspase-3 activation 
Many studies have focused on the combination of vemurafenib with inhibitors of diverse 
and druggable kinases, but combination therapies with agents that activate the apoptotic pathway 
have not been extensively explored.  The lack of exploration, in part, might be attributed to the 
fact that melanoma cells possess multiple defects in their apoptotic signaling pathways upstream 
of the executioner caspase,3,23,24 rendering them resistant to many proapoptotic stimuli. In addition, 
because melanomas have elevated expression of procaspase-3,25,26 PAC-1 should be potent and 
selective for such cells.  Furthermore, it is known that BRAFV600E inhibitors induce apoptotic cell 
death mediated by caspase-3;8 thus, the combination of vemurafenib with PAC-1 could lead to 
dramatically enhanced caspase-3 activity and cancer cell death relative to the effect of either 
single-agent.  
Moreover, detailed proteomics experiments described in chapter 2 have shown that 
MEK1/2 kinases are cleaved by caspase-3 during apoptosis.27,28 Given the transient and 
differential inhibition of MEK1/2 phosphorylation with the clinically used inhibitors,29,30 we 
further hypothesized that combination therapy with PAC-1 will lead to drug-induced degradation 
of MEK1/2 kinases. This strategy would have an advantage over small-molecule MEK1/2 
inhibition and should result in little or no acquired resistance. 
This chapter reports the synergistic activity of PAC-1 + vemurafenib and PAC-1 + 
vemurafenib + trametinib in enhancing caspase-3 activity and apoptotic cell death in BRAFV600E 
melanoma cell lines.  As a result of increased caspase-3 activity and resultant MEK1/2 
degradation, the PAC-1 + vemurafenib combination induces significant reduction in tumor volume 
in a murine xenograft model of BRAFV600E melanoma. In addition, the enhancement of apoptotic 
death and sustained inhibition of MEK1/2 and ERK1/2 phosphorylation in vemurafenib-sensitive 
melanoma significantly delays the regrowth of cells after exposure to vemurafenib.  Finally, PAC-
1 remains effective in vemurafenib-resistant A375VR cells in culture and synergizes with 




3.2. PAC-1 synergizes with vemurafenib in BRAFV600E melanoma cells  
In a panel of nine cell lines of diverse origins and BRAF mutational status, vemurafenib is 
potent (IC50 values between 200–550 nM) only in cell lines harboring the BRAF
V600E mutation, 
consistent with previously reported values (Fig. 3.3A).8 Evaluation of PAC-1 in the same panel of 
cell lines shows that PAC-1 retains similar activity in all cell lines (IC50 values between 1–4 µM), 
regardless of BRAF mutational status (Fig. 3.3A). The ability of the combination of PAC-1 + 
vemurafenib to induce apoptotic cell death was then assessed in these cell lines. Under conditions 
(24 hour incubation with compounds) where neither vemurafenib nor PAC-1 induced significant 
apoptotic death (≤10%) as single agents, the PAC-1 + vemurafenib combination induces 
significant apoptosis (20–45%) in cell lines with the BRAFV600E mutation (Fig. 3.3B). A similar 
trend was also observed when a lower concentration of vemurafenib (0.5 μM) was evaluated in 
combination with PAC-1 in BRAFV600E cell lines (Fig. 3.3C). However, the PAC-1 + vemurafenib 





Figure 3.3. The effect of vemurafenib and PAC-1 in BRAFV600E or BRAFWT cell lines. (A) IC50 values (5 day) of 
vemurafenib and PAC-1 in a panel of nine cell lines. (B) Cell lines with BRAFV600E have significantly higher percent 
of cells undergoing apoptosis (assessed by Annexin V-FITC/PI staining) after treatment with vemurafenib (10 µM) 
and PAC-1 (12 µM) or (C) vemurafenib (0.5 µM) and PAC-1 (12 µM) for 24 h. Dashed horizontal lines represent the 
level of cell death expected from a mere additive effect of the two agents. Values are reported as mean ± SEM of at 
least three independent experiments. P-values shown for 2-way interaction to determine if the combination for 
induction of apoptosis is different from an additive effect (dashed horizontal lines) of individual agents are statistically 
significant (* p<0.05, ** p<0.01, *** p<0.001). Data is adapted with permission from Molecular Cancer Therapeutics 
Ref1 © (2016) American Association for Cancer Research. 
 
3.2.1. PAC-1 + vemurafenib enhances apoptosis in BRAFV600E not BRAFWT cells due to 
increased caspase-3 activity 
In order to more broadly explore the observed synergy, apoptotic death was assessed in 
three human BRAFV600E melanoma cell lines treated with a matrix of concentrations of PAC-1 and 
vemurafenib that induce minimal apoptosis as single agents. In these experiments, large increases 
in the populations of apoptotic cells (beyond the additive effect of single agents alone) were 
observed in A375 (Fig. 3.4A), SK-MEL-5 (Fig. 3.5A) and UACC-62 (Fig. 3.6A). To quantify the 
synergy of this drug combination, combination indices (CI) were calculated. A drug combination 
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that is synergistic will have a CI value less than 1, while a value of 1 reflects an additive effect.31 
93% of the calculated CI values are less than 1 (A375 in Fig. 3.4B, SK-MEL-5 in Fig. 3.5B and 
UACC-62 in Fig. 3.6B), indicating synergism for the combination across all three cell lines tested.  
To assess if the increase in apoptosis was a result of increased activation of executioner 
procaspases, caspase-3/-7 enzymatic activity was evaluated in A375 cells (after lysis) using a 
fluorogenic substrate. In A375 cells treated with vemurafenib or PAC-1 alone (at the same 
concentrations used in Fig. 3.3B), negligible increases in caspase-3 activity were observed at these 
time points and concentrations (Fig. 3.4C). However, when A375 cells were treated with PAC-1 
and vemurafenib, a significant increase in caspase-3 activity was observed as early as 7 hour post-
treatment (Fig. 3.4C).  In Western blot analyses, neither of the single agents had an effect on 
PARP-1 cleavage at these time points and concentrations; however, the combination resulted in 
significant cleaved PARP-1 (Fig. 3.4D), a result of the increased caspase-3/-7 activity in cells 
treated with the PAC-1 + vemurafenib combination. After treatment with the combination for 24 
hours, near-complete cleavage of PARP-1 was observed in A375 cells (Fig. 3.4D). Similar results 
for the caspase-3/-7 activity assay and cleavage of PARP-1 were also observed in SK-MEL-5 
(Figs. 3.5C and D) and UACC-62 cells (Figs. 3.6C and D).  
Consistent with the data in Figs. 3.3B and 3.3C, no enhancement in caspase-3 activity or 
PARP-1 cleavage were observed in two BRAFWT cell lines when treated with the combination of 





Figure 3.4. PAC-1 and vemurafenib powerfully synergize to induce apoptotic death and caspase activity in A375 
cells. (A) Shown is percent apoptotic cell death (assessed by Annexin V/PI staining and flow cytometry) induced after 
24 hours. Values shown are heat mapped with white representing low % apoptotic cell death and red representing high 
% apoptotic cell death.  (B) CI calculated for each combination with Combosyn software. CI values are heat mapped 
with lowest values in green and the highest values in red. (C) Significant caspase-3/-7 enzymatic activity is observed 
in cells treated with the combination of PAC-1 and vemurafenib; PAC-1 and vemurafenib alone have little effect (p-
values vs. DMSO control > 0.1 at all timepoints). Caspase-3/-7 activity in cell lysates was assessed with the 
fluorogenic Ac-DEVD-AFC substrate. Activity is expressed as normalized to minimal and maximal activity observed 
within the assay, with 1 μM staurosporine (STS) as the positive control. (* p<0.05, ** p<0.01, *** p<0.001) (D) PAC-
1 and vemurafenib alone have little effect on PARP-1 cleavage in A3755 cells, but significant PARP-1 cleavage is 
observed via western blot with the combination. Data is adapted with permission from Molecular Cancer Therapeutics 






Figure 3.5. PAC-1 and vemurafenib powerfully synergize to induce apoptotic death and caspase activity in SK-MEL-
5 cells. (A) Shown is percent apoptotic cell death (assessed by Annexin V/PI staining and flow cytometry) induced 
after 24 hours. Values shown are heat mapped with white representing low % apoptotic cell death and red representing 
high % apoptotic cell death.  (B) CI calculated for each combination with Combosyn software. CI values are heat 
mapped with lowest values in green and the highest values in red. (C) Significant caspase-3/-7 enzymatic activity is 
observed in cells treated with the combination of PAC-1 and vemurafenib; PAC-1 and vemurafenib alone have little 
effect (p-values vs. DMSO control > 0.1 at all timepoints). Caspase-3/-7 activity in cell lysates was assessed with the 
fluorogenic Ac-DEVD-AFC substrate. Activity is expressed as normalized to minimal and maximal activity observed 
within the assay, with 1 μM STS as the positive control. (* p<0.05, ** p<0.01, *** p<0.001) (D) PAC-1 and 
vemurafenib alone have little effect on PARP-1 cleavage in SK-MEL-5 cells, but significant PARP-1 cleavage is 
observed via western blot with the combination. Data is adapted with permission from Molecular Cancer Therapeutics 








Figure 3.6. PAC-1 and vemurafenib powerfully synergize to induce apoptotic death and caspase activity in UACC-
62 cells. (A) Shown is percent apoptotic cell death (assessed by Annexin V/PI staining and flow cytometry) induced 
after 24 hours. Values shown are heat mapped with white representing low % apoptotic cell death and red representing 
high % apoptotic cell death.  (B) CI calculated for each combination with Combosyn software. CI values are heat 
mapped with lowest values in green and the highest values in red. (C) Significant caspase-3/-7 enzymatic activity is 
observed in cells treated with the combination of PAC-1 and vemurafenib; PAC-1 and vemurafenib alone have little 
effect (p-values vs. DMSO control > 0.1 at all timepoints). Caspase-3/-7 activity in cell lysates was assessed with the 
fluorogenic Ac-DEVD-AFC substrate. Activity is expressed as normalized to minimal and maximal activity observed 
within the assay, with 1 μM STS as the positive control. (* p<0.05, ** p<0.01, *** p<0.001) (D) PAC-1 and 
vemurafenib alone have little effect on PARP-1 cleavage in UACC-62 cells, but significant PARP-1 cleavage is 
observed via western blot with the combination. Data is adapted with permission from Molecular Cancer Therapeutics 






Figure 3.7. Effect of the PAC-1 and vemurafenib combination in MIA PaCa-2 (mutant KRAS and BRAFWT) and 
CHL-1 (KRASWT and BRAFWT) cell lines with BRAFWT. (A) No effect on procaspase-3 activation is observed in MIA 
PaCa-2 and CHL-1 cell lines when treated with PAC-1 + vemurafenib. Caspase-3/-7 activity in cell lysates was 
assessed with the fluorogenic Ac-DEVD-AFC substrate. Activity is expressed as normalized to minimal and maximal 
activity observed within the assay, with 1 μM STS as the positive control.  (B) No effect on PARP-1 cleavage was 
observed in MIA PaCa-2 cells after 24 h. (C) PAC-1 and vemurafenib have no effect on PARP-1 cleavage in CHL-1 
cells after 24 hour. Values are reported as mean ± SEM of at least three independent experiments. Data is adapted 
with permission from Molecular Cancer Therapeutics Ref1 © (2016) American Association for Cancer Research. 
 
3.2.2. PAC-1 also synergizes with the clinically approved BRAFi + MEKi combination 
therapy 
Addition of a MEK1/2 inhibitor, such as trametinib, is widely used in the clinic to enhance 
the efficacy of vemurafenib in BRAFV600E melanomas.15,16 To explore the effect of PAC-1 with 
this combination, cells were treated with vemurafenib + trametinib, in the presence or absence of 
PAC-1, and apoptosis was assessed. In both A375 and UACC-62 cell lines, vemurafenib + 
trametinib co-treatment led to mere additive increases in the population of apoptotic cells (Fig. 
3.8A). In contrast, the addition of PAC-1 led to a large increase in the population of apoptotic cells, 
beyond the additive effect of single agents alone (Fig. 3.8A). Vemurafenib + trametinib co-
treatment did not lead to PARP-1 cleavage, while addition of PAC-1 led to near quantitative 
cleavage of PARP-1 (Fig. 3.8B). To explore if the increased apoptotic cell death in the presence 
of PAC-1 is a result of enhanced enzymatic activity of executioner caspases, the caspase-3/-7 
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activity of A375 and UACC-62 cells treated with vemurafenib + trametinib, plus or minus PAC-
1, was assessed. Again, a dramatic increase in caspase-3/-7 activity was observed when PAC-1 
was included, an effect that was absent without addition of PAC-1 (Fig. 3.8C).  
 
Figure 3.8. Addition of PAC-1 to the combination of vemurafenib + trametinib powerfully synergizes to induce 
apoptotic death and caspase activity in A375 and UACC-62 cells. (A) Shown is percent apoptotic cell death after 24 
hours. Combination of trametinib (100 nM) and vemurafenib (10 μM) leads to a minimal increase in the population 
of apoptotic cells. Addition of PAC-1 leads to a dramatic increase in the population of apoptotic cells that is beyond 
the additive effect of the three agents. (B) Trametinib and vemurafenib in combination have little effect on PARP-1 
cleavage in A375 and UACC-62 cells, but significant PARP-1 cleavage and reduction in procaspase-3 level are 
observed via Western blot with the addition of PAC-1.  (C) Combination of vemurafenib and trametinib lead to 
additive increase in caspase-3/-7 activity but addition of PAC-1 leads to significant increases in caspase-3/-7 
enzymatic activity in A375 and UACC-62 after 24 h. PAC-1, vemurafenib (10 μM) and trametinib (100 nM) alone 
have little effect (p-values vs. DMSO control > 0.1). Activity is expressed as normalized to the positive control.  
Dashed horizontal lines represent the level of cell death expected from a mere additive effect of the two agents. Values 
are reported as mean ± SEM of at least three experiments. P-values shown for 2-way interaction to determine if the 
combination for induction of apoptosis is different from an additive effect of individual agents are statistically 
significant (* p<0.05, ** p<0.01, *** p<0.001). Data is adapted with permission from Molecular Cancer Therapeutics 
Ref1 © (2016) American Association for Cancer Research. 
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3.2.3. Zinc chelation and on-target inhibition of BRAFV600E are required for synergy 
The PAC-1 derivative PAC-1a lacks the zinc chelating motif and thus does not activate 
procaspase-3 or induce apoptosis.32,33 Use of PAC-1a in combination with vemurafenib did not 
result in a significant increase in the proportion of cells undergoing apoptosis in A375, SK-MEL-
5 or UACC-62 cells (Figs. 3.9A, B, and C). This result is also consistent with the absence of 
increased PARP-1 cleavage in cells treated with the PAC-1a and vemurafenib combination (Fig. 
3.9D), indicating that the cells did not undergo apoptotic death.  
 
Figure 3.9. Effect of PAC-1a (12 µM) vs PAC-1 (12 µM) in combination with vemurafenib (30 µM) in cell lines after 
24 hours in (A) A375, (B) SK-MEL-5 and (C) UACC-62 cell lines as assessed by Annexin V-FITC/PI plots. Percent 
apoptosis reported is normalized relative to DMSO control sample. Dashed horizontal lines represent the level of cell 
death expected from a mere additive effect of the two agents. (D) PAC-1 (12 µM) and vemurafenib (10 µM) alone 
have minimal effect on PARP-1 cleavage in A375 cells, but increased PARP-1 cleavage is observed with the 
combination. PAC-1a (12 µM) in combination with vemurafenib (10 µM) does not increase PARP-1 cleavage. Values 
are reported as mean ± SEM of at least three independent experiments. P-values shown for 2-way interaction to 
determine if the combination for induction of apoptosis is different from an additive effect (dashed horizontal lines) 
of individual agents are statistically significant (*** p<0.001). Data is adapted with permission from Molecular Cancer 
Therapeutics Ref1 © (2016) American Association for Cancer Research. 
 
The lack of PAC-1 + vemurafenib synergy in cell lines harboring BRAFWT (Fig. 3.7) 
suggests that inhibition of ERK1/2 and activation of procaspase-3 are both required to induce the 
dramatic enhancement of apoptotic cell death. Indeed, after 24 hour of treatment with vemurafenib, 
inhibition of ERK1/2 phosphorylation was not observed in BRAFWT cell lines even at high 
concentrations (30 µM) of vemurafenib (Figs. 3.7B and C). This observation is consistent with 
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previous reports where vemurafenib does not inhibit ERK1/2 phosphorylation in BRAFWT cells, 
but paradoxically activates it.8 To further investigate this, A375 (BRAFV600E) cells were treated 
with PAC-1, vemurafenib, or the combination and probed for the presence of cleaved PARP-1 and 
ERK1/2 phosphorylation. After 24 h, phospho-ERK1/2 bands were not observed in cells treated 
with vemurafenib (at 0.5 and 1.0 μM) and the combination (Fig. 3.10A). However, significant 
increases in the amount of cleaved PARP-1 were only observed in cells treated with both PAC-1 
and vemurafenib (Fig. 3.10A). Similar results were also observed in SK-MEL-5 (Fig. 3.10B) and 
UACC-62 cells (Fig. 3.10C). At low concentrations of vemurafenib (0.1 and 0.25 µM), where 
incomplete inhibition of ERK1/2 phosphorylation was observed, slight increase in PARP-1 
cleavage over that single agent effects was also observed (Fig. 3.10A). This result suggests that 
even with incomplete inhibition of ERK1/2 phosphorylation, procaspase-3 activation, which is 
downstream of ERK1/2 signaling, can be enhanced with the addition of PAC-1 to vemurafenib 
treatments.  
 
Figure 3.10. Effect of PAC-1 + vemurafenib on ERK1/2 phosphorylation and PARP-1 cleavage. (A) After 24 h, 
no/low inhibition of ERK1/2 phosphorylation was observed at low concentrations of vemurafenib (0.1 µM and 0.25 
µM). At higher concentrations of vemurafenib (0.5 µM and 1 µM), phosphorylation of ERK1/2 was effectively 
inhibited with or without addition of PAC-1, indicating that effect of PAC-1 is downstream of the MAPK pathway. 
However, cleaved PARP-1 was only observed in cells treated with the vemurafenib/PAC-1 combination, even at 
concentrations of vemurafenib (0.1 and 0.25 µM) where incomplete inhibition of ERK1/2 phosphorylation was 
observed. (B) and (C) In SK-MEL-5 and UACC-62 cells respectively, 24 hour of treatment with vemurafenib (0.5 
µM or 1 µM) inhibited the phosphorylation of ERK1/2 with or without addition of PAC-1, but PARP-1 cleavage is 
only observed in cells co-treated with PAC-1. Data is adapted with permission from Molecular Cancer Therapeutics 
Ref1 © (2016) American Association for Cancer Research. 
 
3.2.4. Caspase-3 activation leads to degradation of MEK1 and MEK2 kinases 
As described in chapter 2, activation of an executioner caspase such as caspase-3 leads to 
the cleavage of hundreds of proteins in the cell. Intriguingly, the protein substrates for caspase-3 
tend to be found in protein complexes or signaling pathways that govern cell fate and survival.27 
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Proteome-wide identification of caspase-3 substrates by the Wells27 and Cravatt28 laboratories 
have independently shown that both MEK1 and MEK2 kinases are cleaved during caspase-3-
mediated apoptosis. Moreover, it has also been shown that MEK1 and MEK2 are the only kinases 
that phosphorylate ERK1/2,34,35 serving as the critical gatekeepers of ERK1/2 activity.14 Given the 
unique observation that addition of PAC-1 to diverse kinase inhibitors leads to enhanced apoptosis, 
we hypothesize that the dramatic increase in caspase-3 activity leads to MEK1 and MEK2 
degradation to inhibit downstream pro-survival signaling.  
To investigate this hypothesis, levels of MEK1 and MEK2 kinases in BRAFV600E cell lines 
were probed following treatment with PAC-1 + vemurafenib or trametinib + vemurafenib. In both 
A375 and SK-MEL-5 cells treated with PAC-1 + vemurafenib for 48 h, dramatic reduction in 
procaspase-3, MEK1, and MEK2 levels were observed, suggesting that procaspase-3 activation 
led to MEK1 and MEK2 degradation (Fig. 3.11). In contrast, when these two cell lines are treated 
with trametinib and vemurafenib, no observable change in the levels of procaspase-3, MEK1, and 




Figure 3.11. PAC-1 combination therapies lead to caspase-3 activation and degradation of MEK1 and MEK2 kinases. 
Procaspase-3 activation leads to dramatic reduction in MEK1 and MEK2 levels in A375 and SK-MEL-5 cells treated 
with PAC-1 (5 μM) + vemurafenib (10 μM) for 48 h. This reduction was not observed in cells treated with trametinib 
(30 nM) + vemurafenib. 
 
To further probe the effect of caspase-3 activation on the degradation of MEK kinases, we 
treated A375 cells with general cytotoxins doxorubicin (Dox) and staurosporine (STS) and probed 
for changes in MEK1 and MEK2 levels. It is important to note that, unlike PAC-1, Dox and STS 
do not directly activate caspase-3 but non-specifically induce apoptosis and caspase-3 activation 
through topoisomerase and pan-kinase inhibition, respectively. Consistent with previous 
results,36,37 robust activation of procaspase-3 was observed in A375 cells treated with Dox and 
STS, leading to near complete degradation of both MEK1 and MEK2 in both samples (Fig. 3.12). 
Taken together, these results indicate the generality of caspase-3-mediated cleavage of MEK1 and 
MEK2 kinases. 
 
Figure 3.12. General cytotoxins lead to procaspase-3 activation and degradation of MEK1 and MEK2 kinases. A375 
cells were treated with Dox and STS for 24 hours. Indicated combinations of PAC-1 (5 μM), vemurafenib (10 μM), 




3.2.5. Degradation of MEK1 and MEK2 kinases leads to sustained inhibition of MEK1/2 and 
ERK1/2 phosphorylation 
Significant inhibition (>80%) of ERK1/2 phosphorylation is necessary for the clinical 
efficacy of targeted kinase inhibitors like vemurafenib.10 Since reactivation of ERK1/2 
phosphorylation was commonly observed in resistant tumors,17,38 MEK1/2 inhibitor was added to 
the treatment regimen to achieve sustained ERK1/2 inhibition. While clinically approved MEK1/2 
inhibitors are effective in inhibiting ERK1/2 phosphorylation, the inhibition of ERK1/2 activity 
disrupts the negative feedback on RAF, resulting in RAF hyper-activation and hyper-
phosphorylation of MEK1/2.14 The rebound in MEK1/2 phosphorylation subsequently leads to 
pathway reactivation. Development of “feedback buster” MEK1/2 inhibitors such as 
trametinib39,40 is intended to mitigate the rebound but that effect is transient29. Therefore, sustained 
inhibition of both MEK1/2 and ERK1/2 remains challenging despite the availability of numerous 
MEK1/2 inhibitors.  
Given that enhanced caspase-3 activity led to degradation of MEK1/2 kinases, we 
hypothesized that PAC-1 combination therapies would lead to sustained inhibition of MEK1/2 and 
ERK1/2 phosphorylation. Addition of PAC-1 to vemurafenib led to inhibition of ERK1/2 
phosphorylation in both A375 (Figs. 3.13A and B) and SK-MEL-5 cells (Fig. 3.13A), consistent 
with results presented in Figs. 3.8B, 3.10A and 3.10B. While sustained inhibition of MEK1/2 
phosphorylation was observed when cells were treated with vemurafenib + PAC-1 due to the 
degradation of MEK1 and MEK2 kinases (Fig. 3.11), a rebound in MEK1/2 phosphorylation was 
rapidly seen in trametinib + vemurafenib treated cells (Fig. 3.13B). This observation is consistent 
with a previous report detailing the transient (6 h) effect of trametinib in inhibiting MEK1/2 
phosphorylation in mutant BRAF melanoma cells.29 These results suggest direct degradation of 




Figure 3.13. Cells treated with PAC-1 and clinically approved kinase inhibitors led to sustained inhibition of MAPK 
signaling. (A) A375 and SK-MEL-5 melanoma cells were treated with PAC-1 (5 μM), vemurafenib (10 μM), 
trametinib (30 nM), or the indicated combinations for 48 h. Sustained inhibition of ERK1/2 and MEK1/2 
phosphorylation were observed in cells treated with either PAC-1 + vemurafenib but not trametinib + vemurafenib. 
(B) Timecourse of phospho-MEK1/2 and phospho-ERK1/2 inhibition in A375 cells. The cells were treated with 
vemurafenib (10 μM), and in combination with PAC-1 (5 μM) or trametinib (30 nM) for 6, 24, or 48 hours. 
 
3.2.6. PAC-1 + vemurafenib have a good safety profile and display potent antitumor activity 
in vivo 
Before determining if PAC-1 + vemurafenib exhibit antitumor activity in vivo, the 
tolerability and safety of this combination were first evaluated in nude mice. In mice treated with 
PAC-1 (i.p. 100 mg/kg once-a-day) + vemurafenib (p.o. 15 mg/kg twice-a-day) for a period of 15 
days, no hematological toxicities were observed (Table 3.1), indicating a favorable safety profile 





Table 3.1. Hematologic and biochemical toxicity of PAC-1 and vemurafenib. Average data from 4 mice treated with 
100 mg/kg PAC-1 once-a-day and 10 mg/kg vemurafenib twice-a-day for 15 days. No clinically significant evidence 
for myelosuppression, renal injury, or hepatic toxicity was identified. *Platelet cell counts were low because platelet 
clumps were observed. Normal range values were obtained from Charles River for female NU/NU mice between 8 to 
10 weeks of age. Table is adapted from Molecular Cancer Therapeutics Ref1 © (2016) American Association for 
Cancer Research. 
Blood chemistry Ave ± SEM Normal Range
1
 
Creatinine (mg/dL) 0.20 ± 0.04 0.2 - 0.4 
BUN (Urea) (mg/dL) 32.3 ± 1.0 11 - 39 
Total Protein (g/dL) 4.7 ± 0.1 4.8 - 6.6 
Albumin (g/dL) 2.2 ± 0.1 2.8 - 4.0 
Globulin (g/dL) 2.5 ± 0.1  
Calcium (mg/dL) 9.2 ± 0.2 9.5 - 12.1 
Phosphorous (mg/dL) 10.8 ± 0.5 8.0 - 15.5 
Sodium (mmol/L) 161.0 ± 0.8 140.7 - 165.1 
Potassium (mmol/L) 7.9 ± 0.2 7.0 - 10.8 
Chloride (mmol/L) 119.0 ± 0.9 108.8 - 133.2 
Glucose (mg/dL) 182.3 ± 12.5 149 - 271 
Alkaline Phos Total (U/L) 70.8 ± 9.0 76 - 301 
ALT (SGPT) (U/L) 50.5 ± 4.6 31 - 115 
Total Bilirubin (mg/dL) 0.3 ± 0.1 0.2 - 0.5 
Cholesterol total (mg/dL) 111.5 ± 4.4 98 - 202 
Platelet Estimate* (10
3
/μL) 229.3 ± 7.5 376 - 1796 
WBC Estimate (10
3
/μL) 3.2 ± 0.4 1.4 - 10.3 
Seg % 31.5 ± 8.7 14.0 - 54.7 
Lymph % 61.5 ± 9.6 23.6 - 79.3 
 
 
To determine the antitumor effect of the PAC-1 + vemurafenib combination in vivo, an 
A375 xenograft model was used.41 In this model, nude mice were inoculated subcutaneously with 
A375 cells, and after allowing the tumors to grow, mice were randomized based upon tumor 
volume into four groups [F=0.03 < Fcritical(3.01)] and dosed with PAC-1, vemurafenib, or the 
combination for 15 days. Treatment with PAC-1 alone led to minimal reduction in tumor mass and 
volume compared to untreated control mice (Figs. 3.14A and B). Mice dosed with vemurafenib 
alone experienced a moderate reduction (53%; p=0.04) in tumor volume and mass compared to 
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control (Figs. 3.14A and B), with 3 out of 8 mice having comparable tumor mass as the control 
mice (Fig. 3.14B). In contrast, mice treated with the combination of PAC-1 and vemurafenib had 
significantly smaller tumor burden compared to control mice (Figs. 3.14A, B, and C). In these 
mice, a 78% reduction in tumor volume was observed (Fig. 3.14A, p=0.0008 vs. control), with 6 
out of 8 mice having tumors less than 0.2 g in mass (Fig. 3.14B), suggesting that addition of PAC-
1 enhances the antitumor effects of vemurafenib in vivo and reduces the variability in response to 
treatment.  
Examination of procaspase-3 levels in the tumor samples by Western blot showed an 
appreciable and consistent reduction in the amount of procaspase-3 only in tumor samples derived 
from mice that received the combination treatment, versus variable responses for the other dosing 
groups (Figs. 3.14C and D). Using immunohistochemical staining, a significant reduction in the 
percentage of Ki-67 expressing cells in tumors treated with PAC-1 + vemurafenib was observed 
(Fig. 3.14E), indicating that the PAC-1 + vemurafenib combination was capable of not only 
amplifying procaspase-3 activation, but also attenuating cell proliferation.  Taken together, the in 
vivo data are consistent with the cell culture results showing that the synergy of PAC-1 + 
vemurafenib leads to increase in caspase-3 activity and induction of apoptotic cell death, as well 





Figure 3.14. The PAC-1+vemurafenib combination retards tumor growth in an A375 subcutaneous mouse xenograft 
model of melanoma. (A) The effect of PAC-1, vemurafenib, and their combination in the A375 model. Mice bearing 
subcutaneous tumors were dosed for 15 days. Mice were dosed with PAC-1 once daily at 100 mg/kg (n=6) via i.p. 
injection, vemurafenib twice daily at 10 mg/kg (n=8) by (p.o.), or the PAC-1+vemurafenib combination (n=8). The 
black line below the x-axis indicates the dosing period for the mice during the study. Tumor volumes are plotted as 
mean ± SEM. (B) Masses of the excised tumors. (C) Tumor lysates were analyzed by Western blot for changes in 
procaspase-3 levels. Actin was used as loading control. Band intensity was quantified using ImageJ. (D) Plot of 
procaspase-3 levels normalized to the actin loading controls. (E) Percentage of cells that are positive for Ki-67 
following immunohistochemical staining of formalin fixed tumor samples. 2000 cells were counted in each sample 
for each of the four treatment groups. P-values shown are with respect to control mice. (* p<0.05, ** p<0.01, *** 
p<0.001) Data is adapted with permission from Molecular Cancer Therapeutics Ref1 © (2016) American Association 




3.2.7. Vemurafenib resistance can be mimicked in cell culture and PAC-1 combination 
therapy dramatically delays the onset of vemurafenib resistance 
The Emax of vemurafenib (the percent cell death induced by high concentrations of 
compound)42 in A375 cells is 96.8±0.3% after 5 days (Fig. 3.15A), indicating that ~3% of A375 
cells are insensitive to vemurafenib. Under the same conditions, PAC-1 has an Emax of 99.4±0.7% 
(Fig. 3.15A), suggesting that PAC-1 kills A375 cells quantitatively, with very few insensitive cells. 
We therefore hypothesized that long term treatment with vemurafenib would lead to re-growth of 
cancer cells, while treatment with PAC-1 should prevent re-growth.  To investigate this hypothesis, 
A375 and SK-MEL-5 cells were plated at low densities and treated continuously with PAC-1 (4 
µM) or vemurafenib (10 µM) for up to 30 days. In A375 and SK-MEL-5 cells treated with 
vemurafenib, regrowth of cells was observed in as early as 20 days (Fig. 3.15B). However, in wells 
treated with PAC-1, no regrowth was observed even after 30 days (Fig. 3.15B). Thus, consistent 
with the higher Emax value, PAC-1 is able to quantitatively kill cells thereby preventing regrowth.  
To investigate if addition of low concentrations of PAC-1 could combine with vemurafenib 
to prevent cancer cell re-growth, A375 and UACC-62 cells were plated at low densities in 96-well 
plates and treated continuously with PAC-1 (1 µM), vemurafenib (5 µM or 10 µM), or the 
combination for up to 20 days. After 5 days, treatment with PAC-1, vemurafenib, or the 
combination each resulted in significant reduction in cell number compared to the control (A375: 
Figs. 3.15C and D; UACC-62: Figs. 3.16A and B). On day 10, there is no observable difference 
between the PAC-1 treated wells and the control. In wells treated with 5 µM or 10 µM 
vemurafenib, cell death was 89.4±1.4% and 93.2±1.1%, respectively. However, in wells where 
A375 cells were treated with 1 µM PAC-1 and 5 µM or 10 µM vemurafenib, increased cell death 
was observed, 96.1±1.0% and 97.9±0.7% respectively. Consequent to achieving more complete 
cell death, a smaller proportion of cells remain in wells treated with both PAC-1 and vemurafenib. 
After 20 days of treatment, significant regrowth of colonies was observed in vemurafenib-only 
treated wells but not in wells receiving the co-treatment (A375: Figs. 3.15C and D; UACC-62: 
Figs. 3.16A and B). This result indicates that the more complete cell death induced by co-treating 




Figure 3.15. Low concentrations of PAC-1 (1 µM) significantly delay cell regrowth in combination with vemurafenib 
in long-term cell culture experiments. (A) Comparison of Emax values in A375 cells treated with vemurafenib and 
PAC-1. (B) A375 and SK-MEL-5 cells treated with PAC-1 (4 μM) or vemurafenib (10 μM) for a duration of 30 days. 
(C) A375 cells were treated with PAC-1, vemurafenib, or the combination. After 5, 10 or 20 days, the wells were 
fixed with 10% trichloroacetic acid, stained with 0.5% sulforhodamine B (SRB) dye, and imaged with BioRad GelDoc 
RX. Day 20 images of control and PAC-1 samples are not shown because the cells were unviable due to overcrowding. 
(D) Quantification of (C) where the SRB dye is dissolved in 10 mM Tris base at pH 10.4, and the absorbance read at 
510 nm. Corrected absorbance at 510 nm was plotted against the days of continuous treatment by normalizing against 
absorbance on Day 0 before the start of treatment. Values are reported as mean ± SEM of at least three experiments. 
T-test performed between wells treated with vemurafenib only versus vemurafenib and PAC-1 (1 μM). On day 10, 
only the wells treated with vemurafenib (10 μM) and PAC-1 (1 μM) is significantly different from vemurafenib (10 
μM) only (p=0.049) treatment. On day 20, wells treated with vemurafenib (5 or 10 μM) and PAC-1 (1 μM) are 
significantly different from vemurafenib (5 or 10 μM), as indicated. (* p<0.05, ** p<0.01, *** p<0.001) Data is 





Figure 3.16. Addition of PAC-1 (1 µM) in the long-term treatment of UACC-62 cells with vemurafenib significantly 
delays cell regrowth. (A) UACC-62 cells were treated with PAC-1, vemurafenib, or the combination. Media was 
washed out every 2-3 days and new compounds were added into each well. After 5, 10 or 20 days, the wells were 
fixed and imaged as described above. Day 20 images of control and PAC-1 samples are not shown because the cells 
were unviable due to overcrowding. (B) Quantification of (A) where the SRB dye is dissolved in 10 mM Tris base at 
pH 10.4, and the absorbance read at 510 nm. Corrected absorbance at 510 nm was plotted against the days of 
continuous treatment by normalizing against absorbance on Day 0 before the start of treatment. Values are reported 
as mean ± SEM of at least three independent experiments. 2-tailed t-test performed between wells treated with 
vemurafenib only versus vemurafenib and PAC-1 (1 μM). On day 10, only the wells treated with vemurafenib (10 
μM) and PAC-1 (1 μM) is significantly different from vemurafenib (10 μM) only (p=0.035) treatment. On day 20, 
wells treated with vemurafenib (5 or 10 μM) and PAC-1 (1 μM) are significantly different from vemurafenib (5 or 10 
μM), as indicated on the graph. (* p<0.05, *** p<0.001) Data is adapted with permission from Molecular Cancer 
Therapeutics Ref1 © (2016) American Association for Cancer Research. 
 
Knowing that secondary activating mutations on MEK kinases are commonly found in 
melanomas resistant to BRAFi + MEKi,17-20 we hypothesized that PAC-1 + vemurafenib would 
be more efficacious than trametinib + vemurafenib in delaying resistance in A375 cells. The 
rationale behind the hypothesis is two-fold: i) PAC-1 + vemurafenib significantly enhances 
apoptotic cell death leading to ii) degradation of MEK kinases to prevent acquisition of secondary 
mutations that lead to resistance. To test this hypothesis, A375 cells were treated with indicated 
concentrations of PAC-1, vemurafenib, trametinib, and their respective combinations for up to 30 
days. Consistent with our previous work, resistant colonies were visibly present in A375 cells 
treated with single-agent vemurafenib as early as 20 days post treatment (Figs. 3.17A and B). In 
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cells treated with trametinib + vemurafenib, resistant colonies were first noted after 25 days of 
continuous treatment. Following 30 days of treatment, more resistant colonies were visible in A375 
cells treated with trametinib and vemurafenib, indicating the presence of BRAFi + MEKi 
resistance (Figs. 3.17A and B). However, emergence of resistant colonies were not observed in 
A375 cells treated with PAC-1 and vemurafenib in the presence or absence of trametinib following 
30 days of treatment (Figs. 3.17A and B), indicating that the double or triple combination is 
significantly more effective in delaying the onset of vemurafenib resistance as compared to the 
clinically used BRAFi + MEKi combination.  
 
Figure 3.17. PAC-1 + vemurafenib is more effective in delaying acquired resistance than the clinically used BRAFi 
+ MEKi combination. (A) A375 cells were treated with PAC-1, vemurafenib, trametinib or the combination. Media 
was washed out every 2-3 days and new compounds were added into each well. After 10, 20, 25, or 30 days, the wells 
were fixed and imaged as described above. Day 20 images of control and PAC-1 samples are not shown because the 
cells were unviable due to overcrowding. (B) Quantification of (A) where the SRB dye is dissolved in 10 mM Tris 
base at pH 10.4, and the absorbance read at 510 nm. Corrected absorbance at 510 nm was plotted against the days of 
continuous treatment by normalizing against absorbance on Day 0 before the start of treatment. Values are reported 
as mean ± SEM of at least three independent experiments. 
 
3.3. PAC-1 remains potent in vemurafenib-resistant BRAFV600E melanomas and synergizes 
with vemurafenib 
3.3.1. PAC-1 is potent in killing vemurafenib-resistant A375 cells (A375VR) 
To assess if PAC-1 remains active in a cell line that has acquired resistance to vemurafenib, 
a vemurafenib-resistant A375VR cell line was generated by growing A375 parental cell line in 
sequentially higher concentrations of vemurafenib (0.5 µM to 1.0 µM) for 2 months. To determine 
the mechanism of resistance of A375VR, genes for MEK1/2, NRAS and AKT were sequenced, 
but no commonly reported mutations that would confer resistance were found.43 Similarly, splice 
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variant of the BRAFV600E mRNA was also not observed.44 Through qPCR, A375VR cells have 
approximately 3-fold higher levels of MDR1 mRNA compared to A375. However, compared to 
up to 1000-fold higher levels of MDR1 mRNA in ovarian cells resistant to doxorubicin or 
cisplatin,45 the level of MDR1 mRNA overexpression is considered low, indicating that resistance 
is unlikely due to dramatic upregulation of MDR phenotype. Vemurafenib kills the A375VR cell 
line with a 5-day IC50 value of 1.5 µM, 12-fold less potent compared to the sensitivity of the 
parental A375 (Fig. 3.18A). Moreover, the vemurafenib Emax for A375VR is 79±6.3%, which is 
14% lower than the parental A375 cell line. While treatment of parental A375 cells with 
vemurafenib (0.5 or 1 µM) for 2 hours results in complete inhibition of ERK1/2 phosphorylation, 
this effect is not observed in A375VR, consistent with resistance of A375VR to vemurafenib and 
continued MAPK signaling (Fig. 3.18B). In contrast, PAC-1 retains activity against A375VR with 
an IC50 value of 2.4 µM (vs 1.2 μM for the parental cell line, Fig. 3.18C) and a similar Emax.    
 
Figure 3.18. PAC-1 retains activity in vemurafenib-resistant A375VR cells (A) Vemurafenib is significantly less 
active in A375R versus parent A375. (B) Treatment with 0.5 or 1 µM of vemurafenib is unable to inhibit 
phosphorylation of ERK1/2 in A375VR after 2 h. Under the same conditions, complete inhibition of ERK1/2 
phosphorylation was observed in the parental A375 cell line. (C) PAC-1 retains activity in the A375R cell line. Values 
are reported as mean ± SEM of at least three independent experiments. Data is adapted with permission from 
Molecular Cancer Therapeutics Ref1 © (2016) American Association for Cancer Research. 
 
3.3.2. PAC-1 synergizes with vemurafenib in A375VR cells in culture and in vivo 
We hypothesized that despite the inability of vemurafenib to inhibit ERK1/2 
phosphorylation and MAPK signaling in the resistant A375VR cell line, the combination might 
retain partial capacity to exert a synergistic effect based on the PARP-1 cleavage observed for 
PAC-1 + vemurafenib treatment, even under conditions of incomplete inhibition of ERK1/2 
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phosphorylation (Fig. 3.10A). To investigate if PAC-1 can re-sensitize A375VR cells to 
vemurafenib-induced apoptosis, A375VR cells were treated with PAC-1 in combination with low 
concentrations of vemurafenib. This combination treatment led to an increase in the proportion of 
cells undergoing apoptosis (Figs. 3.19A and C), suggesting that the addition of PAC-1 can bypass 
the resistance mechanism of A375VR to vemurafenib. This effect was abolished when inactive 
variant PAC-1a was used (Fig. 3.19C). The PAC-1 + vemurafenib combination was synergistic, 
inducing an average of 7.5% higher population of apoptotic cells than predicted by the Bliss 
independence model46 (Figs. 3.19A and B). Finally, to determine if PAC-1 can synergize with 
vemurafenib in vivo, A375VR cells were implanted subcutaneously in nude mice, and the mice 
were dosed daily for 15 days with vemurafenib (10 mg/kg), PAC-1 (100 mg/kg) or the 
combination. Treatment with vemurafenib or PAC-1 alone does not exert any antitumor affect in 
this in vivo model, while treatment with combination led to significant reduction in tumor volume 





Figure 3.19. Effect of the PAC-1 and vemurafenib combination in A375VR cells. (A) Shown is percent apoptotic cell 
death (assessed by Annexin V/PI staining and flow cytometry) induced after 24 hours. (B) The apoptotic cell death 
observed in (A) is greater than that predicted by the Bliss independent model. The excess cell death is calculated as 
[f(observed, apoptotic) – (f(PAC-1, apoptotic) + f(vemurafenib, apoptotic) - f(PAC-1, apoptotic)*f(vemurafenib, apoptotic))]*100%. This indicates that the 
observed effect is synergistic rather than additive. (C) The synergistic effect of PAC-1 and vemurafenib in activating 
apoptosis in A375VR after 24 h. This effect is abolished when the inactive PAC-1a was used. Dashed horizontal lines 
represent the level of cell death expected from a mere additive effect of the two agents. Values are reported as mean 
± SEM of at least three independent experiments. P-values shown for 2-way interaction to determine if the 
combination for induction of apoptosis is different from an additive effect (dashed horizontal lines) of individual 
agents are statistically significant (* p<0.05, ** p<0.01, *** p<0.001). (D) The effect of PAC-1, vemurafenib, and 
their combination in the A375VR xenograft model. Mice bearing subcutaneous tumors were dosed for 15 days. Mice 
were dosed with PAC-1 twice daily at 100 mg/kg (n=7) by i.p. injection, vemurafenib twice daily at 10 mg/kg (n=5) 
by (p.o.), or the PAC-1+vemurafenib combination (n=5). The black line above the x-axis indicates the dosing period 
for the mice during the study. Tumor volumes are plotted as mean + SEM.  P-values shown are with respect to control 
mice.  (* p<0.05) Data is adapted with permission from Molecular Cancer Therapeutics Ref1 © (2016) American 
Association for Cancer Research. 
 
3.4. Discussion and outlook 
Given that the aberrations in the apoptotic signaling cascades in melanoma cells are 
upstream of the activation of procaspase-3, small molecules that directly activate procaspase-3 can 
induce apoptosis by bypassing the defective apoptotic circuitry. Activation of procaspase-3 with 
PAC-1 has been shown previously to have single agent efficacy against melanoma cells in 
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culture,32,47,48 and now we show that PAC-1 + vemurafenib, or PAC-1 + vemurafenib + trametinib, 
are powerfully synergistic in the induction of caspase-3 activity and apoptotic cell death in 
melanomas with BRAFV600E mutation. Enhancement of caspase-3 activity led to MEK1 and MEK2 
degradation and the corresponding sustained inhibition of MEK1/2 and ERK1/2 phosphorylation. 
It is important to point out that sustained inhibition of MEK1/2 phosphorylation was not achieved 
when BRAFV600E cells were treated with trametinib + vemurafenib, due to loss of negative 
feedback on RAF activity induced by MEKi such as trametinib14. Further discussion on this 
observation will be presented in Chapter 4.  
The Emax parameter is a useful metric to assess the ability of a compound to quantitatively 
kill cancer cells in culture;42  Emax values less than 100% imply heterogeneity in the ability of the 
drug to kill the cancer cell population.  Here we show that vemurafenib has an Emax of ~97% in 
BRAFV600E mutant A375 cells, but the Emax value for PAC-1 approaches 100%. Because of this, 
no regrowth of A375 or SK-MEL-5 cells is observed in long-term experiments with PAC-1 as a 
single agent. However, extensive regrowth was observed in A375, UACC-62 and SK-MEL-5 cells 
treated only with vemurafenib for 20 days. With the addition of 1 μM PAC-1 to vemurafenib or 
trametinib + vemurafenib, little to no regrowth was observed in cells. These results suggest that 
addition of 1 µM PAC-1 (a concentration that is readily achieved in human patients49) could be 
effective clinically in delaying resistance. The massive induction of apoptosis likely kills off a 
large proportion of the cells that were initially insensitive to vemurafenib. Furthermore, sustained 
inhibition of MEK1/2 and ERK1/2 phosphorylation severely limits cell proliferation. The 
combination of both effects likely work in tandem to dramatically delay or eliminate the regrowth 
of resistant cells.  
Currently, few options exist for patients who have developed vemurafenib-resistant 
melanomas. The MEK1/2 inhibitor, trametinib, though approved for melanomas with BRAFV600E 
mutation, exerts   limited activity in combination with BRAF inhibitor in patients who have failed 
prior therapy.50 The results presented herein show that PAC-1 still synergizes with vemurafenib to 
exert antitumor effects in vemurafenib-resistant tumors. Therefore, addition of PAC-1 might be a 
viable and alternative therapeutic option for patients whose melanomas have progressed after 
vemurafenib treatment.  The PAC-1 + vemurafenib combination is well tolerated, has a good safety 
profile and exhibits significant antitumor effects in vivo. PAC-1 is currently in a Phase I clinical 
trial (NCT02355535), and both vemurafenib and trametinib are approved first-line treatment for 
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BRAFV600E melanoma. There is thus a clear path to translate the preclinical results to clinical trials 
in melanoma patients harboring the BRAFV600E mutation. A Phase Ib/II trial investigating the 
clinical efficacy of PAC-1 + BRAFi + MEKi involving BRAFV600E melanoma patients who have 
relapsed on BRAFi monotherapy or BRAFi + MEKi therapy has been planned for in 2018.  
Besides melanomas, the BRAFV600E mutation has been reported in several other cancers 
including Erdheim-Chester disease (ECD) (54%)51, Langerhans’-cell histiocytosis (LCH) (57%)51, 
non-small-cell lung cancer (NSCLC) (1.5%)52 and hairy-cell leukemia (100%)53. Clinical trials 
have reported the efficacy of vemurafenib in several non-melanoma cancers harboring the 
BRAFV600E mutation,54,55 including the recent approval of BRAFi + MEKi in NSCLC.  Given this 
clinical data and our current work showing potent synergy between PAC-1, vemurafenib, and 
trametinib in BRAFV600E melanomas, these PAC-1/drug combinations could have efficacy in other 
malignancies harboring the BRAFV600E mutation. 
 
3.5. Materials and methods 
Cell culture and reagents 
A375 (CRL-1619) and CHL-1 (CRL-9446) were purchased from ATCC on 11/5/2014 and 
11/18/2014 respectively. A375SM was provided by Prof. Isiah Fidler (MD Anderson, Texas) on 
10/30/2014. All cell lines except B16-F10, H460, and HCT 116 were cultured in DMEM 
supplemented with 10% FBS (Gemini). B16-F10, H460, and HCT 116 were cultured in RPMI 
with 10% FBS. Vemurafenib, trametinib and Annexin V-FITC (10040-02) were purchased from 
LC Laboratories, MedChemExpress, and SouthernBiotech respectively. The following antibodies 
were purchased from Cell Signaling Technology: anti-PARP-1 (9532), anti-caspase-3 (9662), 
HRP-conjugated anti-β-actin (4967), anti-phospho-ERK1/2 (Thr202/Tyr204) (4370), anti-
ERK1/2 (4695), anti-phospho-MEK1/2 (9121), anti-MEK1 (9146), anti-MEK2 (9147) and HRP 
linked anti-rabbit IgG (7074). Anti-cleaved-PARP-1 (ab32561) antibody was purchased from 
Epitomics. PAC-1 and PAC-1a were synthesized as previously reported.56 
Cell line authentication 
All human cell lines (A375, A375SM, CHL-1, H460, HCT 116, MIA PaCa-2, SK-MEL-
5, and UACC-62) have been authenticated using the PowerPlex16HS Assay (Promega): 15 
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Autosomal Loci, X/Y at the University of Arizona Genetics Core. The test was last performed on 
9/18/2015. Mycoplasma testing has been performed for the A375 cell line using the Mycoplasma 
detect PCR at the University of Illinois Veterinary Diagnostic Lab on 5/13/ 2015.  
Cellular proliferation assays 
1000 – 2000 cells were seeded per well in a 96-well plate and allowed to adhere before 
DMSO solutions of PAC-1 or vemurafenib were added to each well. Proliferation was assessed by 
the SRB assay.   
Annexin V/PI flow cytometry analysis 
70,000 cells were seeded in 12-well plates and allowed to adhere before addition of 
compounds. Cells were treated with compounds for 24 hours at 37 oC, after which they were 
harvested and resuspended in 450 µL of cold buffer (10 mM HEPES, 140 mM NaCl, 2.5 mM 
CaCl2 pH 7.4) premixed with Annexin V-FITC and PI (0.55 µg/mL) dyes. Samples were analyzed 
on a BD Biosciences LSR II flow cytometer and data analysis was performed using FCS Express 
V3-2. 
Caspase-3/-7 activity assay 
5,000-8,000 cells were plated in 96 well plates and allowed to adhere. Cells were treated 
with 1 µM of staurosporine for 24 hours or with 13 µM of raptinal57 for 3 hours as positive control, 
DMSO as negative control and indicated concentrations of PAC-1 and vemurafenib for 0, 2, 4, 7, 
10, 12, 16, 20 or 24 h. Plates were then assessed for caspase-3/7 activity via addition of bifunctional 
lysis and activity buffer (200 mM HEPES, 400 mM NaCl, 40 mM DTT, 0.4 mM EDTA, 1% 
Triton-X, pH 7.4) with 20 µM of Ac-DEVD-AFC (Cayman Chemicals) as the fluorogenic 
substrate (λex=400 nm, λem=505 nm). Plates were pre-incubated at 37
 oC at 30 min in the Synergy 
multi-mode reader (BioTek) then read for 30 min at 3 min intervals. The slopes for each well were 
calculated. Activity is expresses as normalized to minimal and maximal activity observed within 
the assay.  
In vitro resistance assay 
800 A375 or UACC-62 cells were plated in 96-well plates and allowed to attach overnight. 
The next day, vemurafenib (5 or 10 µM) or PAC-1 (1 µM) were treated in six technical replicates 
for 5, 10 and 20 days. Fresh media and compounds were added every 2-3 days for the duration of 
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the study. At the end of 5, 10 or 20 days, the wells were fixed with 10% cold trichloroacetic acid 
for 1 hour at 4 oC. The wells were then washed, allowed to dry and stained with 0.5% SRB dye for 
30 min at room temperature. The wells were then washed with 0.1% acetic acid and allowed to 
dry. At this point, images of the plates were taken with GelDoc XR (BioRad). Finally, 200 µL of 
10 mM Tris base (pH > 10.4) was added into well and the absorbance at 510 nm were read using 
SpectraMax Plus (Molecular Devices). The absorbance at 510 nm is plotted against the days post 
treatment as an indication of cell proliferation over the time course of the experiment.  
In experiments comparing efficacy of PAC-1 + vemurafenib versus trametinib + 
vemurafenib, 100-250 A375 cells were seeded and allowed to adhere overnight. The next day, 
cells were treated with indicated concentrations of PAC-1, vemurafenib or trametinib for 10, 20, 
25 or 30 days. Media was refreshed with new compounds added every 2–3  days. At the end of the 
incubation period, cells were fixed, stained with SRB, imaged using GelDox XR (BioRad), and 
absorbance at 510 nm read using SpectraMax Plus (Molecular Devices) plate reader.  
Immunoblotting 
Cells and tumor tissues were lysed using RIPA buffer containing phosphatase and protease 
inhibitor cocktail (Calbiochem). The protein concentration of each sample was determined by the 
BCA assay (Pierce). Cell lysates containing 20 µg of protein was loaded into each lane of 4-20% 
gradient gels (BioRad) for SDS-PAGE. Proteins were transferred onto PDVF membrane for 
Western blot analysis.  
PCR and sequencing 
A375 and A375VR cells were lysed and RNA extracted using the RNeasy kit (Qiagen). 
900 ng of RNA was used for reverse transcription reaction using iScript cDNA synthesis kit 
(BioRad). qPCR reactions were ran on the 7900HT fast real-time PCR system (Applied 
Biosystems). Regular PCR reactions were ran using the MyFi Mix PCR kit (Bioline) for 35 cycles 
and ran on a 1% agarose gel. Target amplicons were gel extracted and sequenced at the UIUC core 
sequencing facility. Primers used are listed below.  
MDR1 F ACACCATGGGGAAGGTGAAG 
MDR1 R GTGACCAGGCGCCCAATA 
GAPDH F ACACCATGGGGAAGGTGAAG 
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GAPDH R GTGACCAGGCGCCCAATA 
BRAF F GGCTCTCGGTTATAAGATGGC 
BRAF R ACAGGAAACGCACCATATCC 
MEK1 Amp F CGTTACCCGGGTCCAAAATG 
MEK1 Amp R CTTTGTCACAGGTGAAATGC 
MEK1 Seq F CATGGATGGAGGTTCTCTGG 
MEK1 Seq R AGGGCTTGACATCTCTGTGC 
MEK2 Amp F CTCCCGGCCCGCCCCCTATG 
MEK2 Amp R GTGGAGGCGCCAGCCTGTCC 
MEK2 Seq F GTCAGCATCGCGGTTCTCC 
MEK2 Seq R TCACCCCGAAGTCACACAG 
NRAS F AGCTTGAGGTTCTTGCTGGT 
NRAS R TCAGGACCAGGGTGTCAGTG 
AKT1 F AGCGCCAGCCTGAGAGGA 
AKT1 Amp R TCTCCATCCCTCCAAGCTAT 
AKT1 Seq R GACAGGTGGAAGAACAGCT 
 
A375 and A375VR xenograft model 
All animal studies were performed in accordance with UIUC IACUC guidelines (protocol 
no. 14292). 0.1 mL of A375 or A375VR in 1:1 DMEM:matrigel (Corning) was injected into the 
right flank of 6-7 (A375) or 5 (A375VR) week old female athymic nude mice (Charles River). In 
the both models, the mice were randomized into four groups: control, 100 mg/kg PAC-1, 10 mg/kg 
vemurafenib, and the combination of 100 mg/kg PAC-1 and 10 mg/kg vemurafenib (n=8). Initial 
tumor volume measurements were taken and dosing was initiated for a period of 15 days. 
Vemurafenib was formulated as 5% DMSO in 1% methyl cellulose and given twice daily by oral 
gavage (p.o.). PAC-1 was formulated in 200 mg/mL hydroxypropyl-β-cyclodextrin at pH 5.5 and 
given by intraperitoneal (i.p.) injection. Tumor length and width measurements were taken three 
times a week and volume was calculated as 0.52*L*W2. At the end of the study, the mice were 





Immunohistochemistry of A375 tumors and quantification of Ki-67 index 
Immunohistochemistry (IHC) was performed on 4 µm-thick formalin-fixed paraffin-
embedded A375 tumors after H&E staining confirmed the presence of a neoplastic cell population 
along with adequate tissue integrity. Antibody against Ki-67 (Biocare Medical #CRM325) was 
used for IHC and staining was visualized using the IntelliPATH FLX DAB chromogen kit (Biocare 
Medical #IPK 5010 G80). Human tonsil was used as the positive control tissue. Polymer negative 
control serum (mouse and rabbit) (Biocare Medical #NC499) was substituted for the primary 
antibody as a negative control. For quantification of Ki-67 index, 2000 neoplastic cells were 
counted and the percentage of positive cells was calculated. In tumors too small to quantify 2000 
cells, the maximal number of neoplastic cells were counted. All slides were reviewed by a single 
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Chapter 4. PAC-1 + kinase inhibitors in EGFR+, EML4-ALK+, and BCR-ABL+ cancers 
Portions of this chapter have been submitted for publication.  
4.1. Introduction 
4.1.1. Driver oncogenes affect the mitogen-activated protein kinase (MAPK) pathway  
 As discussed in chapters 2 and 3, most driver oncogenes or fusion kinases affect the MAPK 
or PI3K/AKT pathways.1 The BRAFV600E mutation discussed in chapter 3 is a well-studied kinase 
that is mutated in the MAPK pathway. Besides BRAF, EGFR, ALK, ABL, and RAS are oncogenes 
that are frequently altered in this pathway (Fig. 4.1).1 While many mutant oncogenes have been 
identified, only mutations or alterations to EGFR, ALK, and ABL kinases can be clinically targeted 
thus far using specific kinase inhibitions. This chapter describes our efforts to assess if PAC-1 can 
be combined with kinase inhibitors targeting mutant EGFR, EML4-ALK, and BCR-ABL, to 
enhance apoptotic cell death and ultimately delay resistance.  
 
Figure 4.1. MAPK signaling is frequently altered in cancer cells to drive growth factor independent proliferation and 
survival. EGFR, ALK, ABL, RAS, and BRAF (highlighted in red) are targets commonly mutated in a wide variety of 
cancers.  
 
4.1.1.1. EGFRT90M is a commonly found resistance mechanism to first-generation EGFR 
inhibitors and osimertinib as an approved inhibitor 
Alterations in the EGFR gene that are found in non-small cell lung cancer (NSCLC) 
typically occur in the kinase domain, to constitutively activate EGFR activity (Fig. 4.2A).2 EGFR 
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alterations occur in 10–35% of NSCLC3-5, and >90% of these alterations involve either exon 19 
deletion in EGFR or the L858R mutation.2 Gefitinib, a first generation mutant EGFR inhibitor, 
was first evaluated and approved in 2003 for NSCLC patients unselected for EGFR mutation 
status.6 However, it was subsequently withdrawn due to the lack of improvement in overall 
survival7 compared to chemotherapy. Follow-up analyses revealed that gefitinib improved 
progression-free survival (PFS) only in patients harboring EGFR mutations,3,5 permitting its 
approval in this patient population in 2015. Similarly, erlotinib was approved in 2004 based on 
clinical trials in an unselected patient population.8 Fortunately, follow-up clinical trials 
demonstrate benefit of erlotinib in extending overall survival in NSCLC patients with EGFR 
overexpression or mutation, allowing it to retain FDA approval.9,10  
Despite the fact both gefitinib and erlotinib were first approved without knowledge of its 
intended molecular target, both agents are potent in inducing rapid tumor shrinkage in >60% 
patients with an activating EGFR mutation.11 Unfortunately, response to these agents was not 
durable, with resistance to therapy occurring within a year of therapy.11  Sequencing the resistant 
tumors found that ~50% of them harbor an additional T790M mutation at the gatekeeper residue 
(Fig. 4.2B).11 While the additional T790M mutation minimally alters the dissociation constant 
(KD) for gefitinib or erlotinib, the binding affinity (Km) for ATP is increased by two orders of 
magnitude, rendering the inhibitors less potent in competing with ATP for occupancy in the kinase 
active site.12 Interestingly, X-ray crystal structures reveal the presence of a cysteine residue at 
position 797, in close proximity to T790M.12  
To overcome resistance due to the T790M mutation, several irreversible EGFR inhibitors 
that target C797 have been developed to outcompete ATP for binding to the kinase active site.13-
15 One such irreversible inhibitor is osimertinib (Fig. 4.3) which consists of an acrylamide to act 
as the Michael acceptor to bind to C797, making it a potent inhibitor against mutant EGFR with 
or without the T90M mutation.15 Based on superior PFS and objective response rates (ORR),16,17 
the FDA approved osimertinib in 2015 for use in mutant EGFR NSCLC patients who had 
progressed upon first-generation inhibitors and harbored the T790M mutation (Fig. 4.2B). 
Mechanistically, osimertinib binds to EGFRT790M to inhibit constitutive EGFR phosphorylation, 
thereby inhibiting downstream ERK1/2 activity, and thus, MAPK signaling.15,18  As with most 
targeted agents in the clinic, treatment with osimertinib eventually leads to the emergence of drug-
resistant cancer within a year of therapy initiation. Mutation of Cys 797 to Ser 797, which is critical 
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for the binding of osimertinib to EGFRT790M, is observed in ~40% of the patients treated with 
osimertinib (Fig. 4.2B).19 The C797S mutation abolishes osimertinib binding to EGFR, thus 
compromising its efficacy.19  Moreover, tumors harboring gain-of-function mutations or copy-
number amplification in KRAS18 (which occurs downstream of EGFR) were also observed (Fig. 
4.2B), obliterating the effect of EGFRT790M inhibition by osimertinib. Similar to vemurafenib, the 
rapid onset of resistance limits the clinical utility of osimertinib in managing EGFRT790M 
NSCLC.18-20 Currently, limited therapeutic options exist for patients with osimertinib-resistant 
tumors.   
 
Figure 4.2. Mutant EGFR constitutively activates MAPK signaling and drug resistance mechanisms exist to reactivate 
MAPK. (A) In normal cells, presence of EGF activates EGFR-mediated growth signaling. However, in cells with 
mutant EGFR, constitutive activation occurs in the absence of growth ligand, leading to oncogenesis. (B) Selection of 





Figure 4.3. Structures of first generation EGFR inhibitors gefitinib and erlotinib. The EGFRT790M inhibitor osimertinib 
consists of an acrylamide warhead highlighted in blue.  
 
4.1.1.2. EML4-ALK is a driver oncogene in NSCLC and ceritinib as an approved inhibitor 
 Besides alterations to EGFR, the EML4-ALK fusion protein is also found in ~3–7% of 
NSCLC.21 First identified in 2007, the fusion of N-terminus of EML4 with the C-terminus tyrosine 
kinase domain of ALK, alters the cellular localization of ALK from the cell membrane to the 
cytoplasm (Fig. 4.4A).22 In the fusion protein, EML4 facilitates the ligand-independent 
dimerization of ALK, leading to constitutive activation of ALK kinase activity.22 The resultant 
kinase activity is highly oncogenic in cells and in vivo.22 The identification of EML4-ALK as a 
driver of NSCLC led to the rapid approval of the fusion-specific inhibitor crizotinib (Fig. 4.5) 
based on superior ORR and PFS compared to platinum-based chemotherapy.23 Despite the initial 
enthusiasm of crizotinib in the clinic, resistance was rapidly observed, with ~30% of patients 
harboring secondary mutations on ALK that abolish inhibitor efficacy (Fig. 4.4B).24  
Besides inhibiting EML4-ALK, crizotinib also inhibits c-Met and ROS1 with similar or 
better potency.25 To minimize the off-target effects on c-Met and overcome resistance to crizotinib, 
second generation inhibitors such as ceritinib (Fig. 4.5) have been developed.26 In particular, 
ceritinib is active against crizotinib-resistant tumors with secondary ALK mutations (Fig 4.4B).26 
It potently inhibits ERK1/2 phosphorylation and induces apoptosis.26 Based on its activity against 
crizotinib-resistant tumors, improved ORR and PFS, ceritinib was approved by the FDA in 2014.27 




Figure 4.4. EML4-ALK promotes activation of MAPK signaling and drug resistance mechanisms exist to reactivate 
MAPK. (A) In normal cells, ALK is located at the membrane bound receptor tyrosine kinase. Presence of growth 
factor activates ALK-mediated growth signaling. However, the cellular localization of ALK is altered in cells with 
EML4-ALK. This promotes dimerization of ALK to constitutively activate MAPK, leading to oncogenesis. (B) 
Selection of ALKi-resistant NSCLC tumors following treatment with crizotinib or ceritinib.  
 
 
Figure 4.5. First and second generation EML4-ALK inhibitors crizotinib and ceritinib.  
 
4.1.1.3. BCR-ABL is a driver oncogene for CML and imatinib as an approved inhibitor 
 A unique feature of CML is that >95% of the cancer is driven by the BCR-ABL oncogene.29 
Similar to EML4-ALK, BCR-ABL is a fusion of BCR at the N-terminus with the C-terminus 
tyrosine kinase domain of ABL.30,31 The coiled-coil (CC) domain found in the BCR region of the 
fusion protein promotes the auto-dimerization of BCR-ABL and activation of RAS (Fig. 4.6A).31,32 
Unlike ABL kinase whose activity is tightly regulated, aberrant phosphorylation of BCR-ABL, 
leads to constitutive activation of its kinase activity, independent of growth ligand signaling.31,32 
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Not surprisingly, the aberrant kinase activity of BCR-ABL leads to oncogenesis in CML cells.30 
As the first approved inhibitor of BCR-ABL, treatment of BCR-ABL+ CML patients with imatinib 
(Fig. 4.7), led to dramatically improved response rates and overall survival, replacing stem cell 
transplant as the standard-of-care for CML.33 At the molecular level, imatinib inhibits BCR-ABL 
activity, shutting down downstream signaling mediated by ERK1/2. Inhibition of the ERK1/2, and 
thus the MAPK pathway, leads to apoptotic cell death.31 While durable response to imatinib has 
been observed in the majority of CML patients, resistance to imatinib is still observed in up to 33% 
of the patient population, leading to the development of second and third generation inhibitors 
(Fig. 4.6B).32,34  
 
Figure 4.6. BCR-ABL activates MAPK signaling and drug resistance mechanisms exist to reactivate MAPK. (A) In 
normal cells, presence of growth factor activates ALK-mediated growth signaling. However, in cells with EML4-
ALK, constitutive activation occurs in the absence of growth ligand, leading to oncogenesis. (B) Selection of ABLi-




Figure 4.7. Structure of first-generation BCR-ABL inhibitor imatinib.  
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4.1.2. Combination of PAC-1 with diverse kinase inhibitors as a strategy to delay acquired 
resistance 
Reactivation of the MAPK pathway is responsible for acquired resistance to mutant EGFR-
,18-20 EML4-ALK-,16,22 or BCR-ABL-34 driven cancers. Upfront combination therapy with a 
MEK1/2 inhibitor (e.g. trametinib) has been investigated in an effort to delay resistance.18,35-38 
Given the transient and differential inhibition of MEK1/2 activity with the clinically used 
inhibitors,39,40 enzymatic degradation of MEK1/2 kinases would have an advantage over direct 
inhibition. As described in chapter 3, PAC-1 in combination vemurafenib enhances caspase-
mediated degradation of MEK1/2 kinases in melanoma cell lines harboring BRAFV600E to delay 
the onset of resistance,41 suggesting the feasibility of this strategy. Here we assess PAC-1 in 
combination with three different clinically approved inhibitors targeting three different kinases 
that signal through the MAPK pathway. These combinations dramatically enhance caspase-3 
activity and induce degradation of MEK1/2 kinases. Adding PAC-1 to kinase inhibitors targeting 
EGFRT790M (osimertinib), EML4-ALK (ceritinib), or BCR-ABL (imatinib) enhances MEK1 and 
MEK2 degradation, leading to durable inhibition of MEK1/2 and ERK1/2 phosphorylation, 
enhanced apoptotic cell death, and markedly delayed or eliminated acquired resistance. 
 
4.2. Effect of procaspase-3 activation in NSCLC and CML cells treated with PAC-1 + diverse 
kinase inhibitors  
4.2.1. Combination therapy enhances apoptosis due to increased caspase-3 activity 
As shown in Fig. 4.8, PAC-1 significantly increases the caspase-3 activity in osimertinib-
treated non-small cell lung cancer (NSCLC) cell lines H1975 (EGFRL858R+T790M) and PC-9 GR 
(EGFRex19del+T790M). Increased PARP-1 cleavage and disappearance of the procaspase-3 band were 
also observed in both cell lines (Figs. 4.8A and B). A similar effect is also observed in H3122 
NSCLC cells (harboring the fusion kinase EML4-ALK) co-treated with PAC-1 and ceritinib (Fig. 
4.8C) and K-562 chronic myelogenous leukemia (CML) cells (harboring the fusion kinase BCR-
ABL) treated with PAC-1 and imatinib (Fig. 4.8D). As a result of increased caspase-3 activity, a 
significantly larger population of cells treated with the combination of PAC-1 and osimertinib/ 
ceritinib/ imatinib die via apoptosis (Figs. 4.9A–C). Collectively these results demonstrate that, in 
addition to general cytotoxins and inhibitors against BRAFV600E,41-44 PAC-1 is able to broadly 
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enhance the caspase-3 activity of kinase inhibitors against EGFRT790M, EML4-ALK, and BCR-
ABL. 
 
Figure 4.8. Enhancement of caspase-3 activity following co-treatment of cancer cells with PAC-1 and diverse targeted 
kinase inhibitors. Negligible increases in caspase-3 activity or PARP-1 cleavage was observed in (A) H1975 and (B) 
PC-9 GR NSCLC cells treated with DMSO, single-agent PAC-1 (5 μM) or osimertinib. In cells treated with PAC-1 + 
osimertinib, dramatic increases in caspase-3 activity was observed as early as 36 h post-treatment. Significant PARP-
1 cleavage and reduction in procaspase-3 levels were observed after 48 h, consistent with results obtained from the 
caspase-3 activity assay. (C) H3122 NSCLC cells were treated with PAC-1 (5 μM) + ceritinib for varying periods of 
time and a significant increase in caspase-3 activity is observed. Increased PARP-1 cleavage and reduction in 
procaspase-3 levels were also observed after a 48 h treatment. (D) Significant enhancement of caspase-3 activity was 
also observed in K-562 cells treated with PAC-1 (7.5 μM) + imatinib with negligible single-agent activity. Following 
48 h of PAC-1 + imatinib treatment, increased PARP-1 cleavage and procaspase-3 activation were also observed. 
Values shown are averages of at least 3 experiments, error bars are s.e.m. p values shown for two-way interaction to 
determine if the combination is different from an additive effect of individual agents are statistically different (* 





Figure 4.9. Enhanced apoptotic cell death in cells treated with PAC-1 and clinically approved targeted kinase 
inhibitors. (A) EGFRT790M cells and (B) H3122 cells were treated with indicated concentrations of PAC-1 + 
osimertinib or PAC-1 + ceritinib, respectively for 48 h.  (C) K-562 cells were treated with indicated concentrations of 
PAC-1 + imatinib for 72 h. Cells were then stained with Annexin V-FITC and PI dyes and analyzed via flow 
cytometry. Data shown is average of at least three independent experiments and error bars are s.e.m. The dashed 
horizontal lines on the bar graphs represent the additive effect of individual agents.   
 
4.2.2. Enhanced caspase-3 activity leads to degradation of MEK1 and MEK2 kinases 
Based on prior work with PAC-1 + vemurafenib in BRAFV600E cells, we hypothesized that 
the enhanced caspase-3 activity (Fig. 4.8) observed in EGFRT790M, EML4-ALK, and BCR-ABL 
cells would similarly lead to degradation of MEK1 and MEK2 kinases. To investigate this 
hypothesis, changes in procaspase-3, MEK1, and MEK2 levels in EGFRT790M, EML4-ALK, and 
BCR-ABL cells were assessed following combination treatment with PAC-1 and kinase inhibitors 
specific for those alterations. In both H1975 and PC-9 GR cells, treatment with PAC-1 and 
osimertinib led to dramatic reduction in procaspase-3, MEK1, and MEK2 levels (Fig. 4.10A), but 
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not when the inactive inhibitor gefitinib45 (Fig. 4.10B) was used. Using a lower concentration of 
osimertinib (2.5 nM) also led to degradation of MEK1 and MEK2 kinases (Fig. 4.10C). 
Importantly, co-treatment with trametinib and osimertinib did not lead to reduction in MEK1 and 
MEK2 levels in both cell lines (Fig. 4.10A), similar to that observed in BRAFV600E cell lines. 
 
Figure 4.10. PAC-1 + osimertinib lead to caspase-3 activation and degradation of MEK1 and MEK2 kinases. (A) 
Procaspase-3 activation leads to dramatic reduction in MEK1 and MEK2 levels in A375 and SK-MEL-5 cells treated 
with PAC-1 (5 μM) + vemurafenib (10 μM) for 48 hours. This reduction was not observed in cells treated with 
trametinib (30 nM) + vemurafenib. (B) IC50 values of PAC-1, osimertinib, and gefitinib in PC-9 GR and H1975 cells 
following a 5-day incubation. Data shown is average of at least three independent experiments and error bars are s.e.m. 
(C) Degradation of MEK1 and MEK2 kinases also occur in EGFRT790M cells treated with lower concentrations of 
osimertinib + PAC-1. 
 
 Degradation of MEK1 and MEK2 was also seen in H3122 cells when they were co-treated 
with PAC-1 + ceritinib (Fig. 4.11A), even at reduced concentrations of ceritinib (Fig. 4.11B). Co-
treatment with trametinib and ceritinib did not lead to reduction in MEK1 and MEK2 levels in 
H3122 cells (Fig. 4.11A), consistent with data obtained in BRAFV600E and EGFRT790M cells. 
Extensive procaspase-3 activation was observed in K-562 cells treated with either PAC-1 + 
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imatinib or trametinib + imatinib. Consequently, degradation of MEK1 and MEK2 kinases was 
observed in both samples (Fig. 4.11C). Varying the concentration of imatinib used also led 
reduction in MEK1 and MEK2 levels (Fig. 4.11D).  
 
Figure 4.11. Effect of PAC-1 in combination with either ceritinib or imatinib in H3122 (EML4-ALK) cells or K-562 
(BCR-ABL) cells. (A) MEK1 and MEK2 degradation were observed in H3122 cells treated with PAC-1 (5 μM) + 
ceritinib (30 nM) for 48 hours but not in cells treated with trametinib (30 nM) + ceritinib. (B) At a lower concentration 
of ceritinib (15 nM), the combination also led to MEK1 and MEK2 kinase degradation. (C) Treatment of K-562 cells 
with imatinib in combination with either PAC-1 or trametinib for 48 hours led to procaspase-3 activation and MEK1 
and MEK2 degradation. (D) After 48 hours, lower concentration of imatinib (80 nM) in combination with PAC-1 also 
led to procaspase-3 and resultant degradation of MEK1 and MEK2 kinases.  
 
To further validate the effect of caspase-3 activation on the degradation of MEK1 and 
MEK2 kinases, we treated PC-9 GR, H1975, H3122, and K-562 cells with general cytotoxins like 
doxorubicin (Dox) or staurosporine (STS) to non-specifically induce apoptosis and caspase-3 
activation. In all these cell lines, activation of procaspase-3 led to degradation of MEK1 and MEK2 
kinases (Fig. 4.12). Taken together, these results indicate the generality of caspase-3-mediated 




Figure 4.12. General cytotoxins lead to procaspase-3 activation and degradation of MEK1 and MEK2 kinases in a 
diverse panel of cell lines. Cells were treated with 5 μM of Dox or 1 μM of STS for 24 hours in each experiment. Cells 
were treated with individual kinase inhibitors, in combination with either PAC-1 or trametinib, for 48 hours. 30 nM 
trametinib was used in all cell lines. 5 μM PAC-1 was used in all cell lines except K-562. In K-562 cells, 7.5 μM PAC-
1 was used instead. 4 nM osimertinib was used in the EGFRT790M cell lines, 30 nM ceritinib was used in H3122 cells, 
and 100 nM imatinib was used in K-562 cells. 
 
4.2.3. Degradation of MEK1 and MEK2 kinases leads to sustained inhibition of MEK1/2 and 
ERK1/2 phosphorylation  
 In BRAFV600E cells treated with PAC-1 + vemurafenib, degradation of MEK1 and MEK2 
kinases led to the sustained inhibition of MEK1/2 and ERK1/2 phosphorylation. Given that 
degradation of MEK1 and MEK2 kinases also occurs in cells treated with PAC-1 + osimertinib, 
we hypothesized a similar effect should be observed in EGFRT790M cells treated with this 
combination.  
To explore the generality of this effect, H1975 and PC-9 GR cells were treated with PAC-
1 and osimertinib and probed for changes ERK1/2 and MEK1/2 phosphorylation. As seen in Figs. 
4.13A and B, EGFRT790M cells treated with PAC-1 and osimertinib led to sustained loss of ERK1/2 
and MEK1/2 phosphorylation, as a result of MEK1 and MEK2 degradation (Fig. 4.10A). Using 
PAC-1 and gefitinib, no corresponding reduction in ERK1/2 or MEK1/2 phosphorylation is 
observed (Fig. 4.13A), indicating that the effect with osimertinib is specific for the EGFRT790M 
target. At a lower concentration of osimertinib, sustained inhibition of MEK1/2 and ERK1/2 
phosphorylation (Fig. 4.13C) corresponding to degradation of MEK1 and MEK2 kinases was also 
observed (Fig. 4.10C). Rapid rebound of MEK1/2 phosphorylation similarly occurs within 24 hour 
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treatment with osimertinib and trametinib but in cells treated with osimertinib and PAC-1 (Fig. 
4.13B), mirroring the effect seen in BRAFV600E cells.  
 
Figure 4.13. Cells treated with PAC-1 and osimertinib have sustained inhibition of MAPK signaling. (A) After 48 
hours of treatment with PAC-1 (5 μM) + osimertinib (4 nM), sustained inhibition of both MEK1/2 and ERK1/2 
phosphorylation were observed in H1975 and PC-9 GR cells. Treatment with PAC-1 + gefitinib (4 nM) for a similar 
time period did not lead to similar observations. Sustained inhibition of MEK1/2 phosphorylation was also not 
observed in cells treated with trametinib (30 nM) + osimertinib. (B) Timecourse of phospho-MEK1/2 and phospho-
ERK1/2 inhibition in PC-9 GR cells treated with DMSO, osimertinib, osimertinib + PAC-1 or osimertinib + trametinib 
for 6, 24, or 48 hours. (C) Sustained inhibition of MEK1/2 and ERK1/2 phosphorylation was still observed in 
EGFRT790M cells after 48 hour of treatment with PAC-1 and lower concentration of osimertinib (2.5 nM).  
 
In a similar fashion, H3122 cells (EML4-ALK) were treated with PAC-1 + ceritinib or 
trametinib + ceritinib and probed for changes in ERK1/2 and MEK1/2 phosphorylation. In this 
case, H3122 cells co-treated with PAC-1 + ceritinib for 48 hours also led to sustained reduction in 
ERK1/2 and MEK1/2 phosphorylation (Figs. 4.14A and B), which can be attributed to the caspase-
3-mediated degradation of MEK1 and MEK2 kinases (Fig. 4.11A). At a lower concentration of 
ceritinib, sustained inhibition of MEK1/2 and ERK1/2 phosphorylation (Fig. 4.14C) due to 
degradation of MEK1 and MEK2 kinases was also observed (Fig. 4.11B). Similarly, transient 
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inhibition of MEK1/2 phosphorylation was also observed in H3122 cells treated with trametinib 
and ceritinib (Fig. 4.14B), consistent with results seen in BRAFV600E and EGFRT790M cells.  
 
Figure 4.14. PAC-1 + ceritinib lead to sustained MEK1/2 phosphorylation in H3122 cells. (A) H3122 cells treated 
with PAC-1 (5 μM) + ceritinib (30 nM) for 48 hours led to sustained inhibition of MEK1/2 and ERK1/2 
phosphorylation. However, trametinib (30 nM) + ceritinib treatment did not inhibit MEK1/2 phosphorylation. (B) 
Timecourse of phospho-MEK1/2 and phospho-ERK1/2 inhibition. H3122 cells were treated with DMSO, ceritinib, 
ceritinib + PAC-1 or ceritinib + trametinib for 6, 24, or 48 hours. Little or no inhibition of MEK1/2 phosphorylation 
was observed with trametinib co-treatment. (C) At a lower concentration of ceritinib (15 nM), the combination led to 
sustained inhibition of MEK1/2 and ERK1/2 phosphorylation. 
 
Finally, in K-562 cells expressing BCR-ABL, co-treatment with PAC-1 and imatinib also 
lead to sustained inhibition of ERK1/2 and MEK1/2 phosphorylation (Fig. 4.15A) due to extensive 
degradation of MEK1 and MEK2 kinases (Fig. 4.11C). It should be noted that rebound of MEK1/2 
phosphorylation was not observed in cells treated with trametinib + imatinib for 48 hours (Fig. 
4.15A), since degradation of MEK1 and MEK2 kinases was also observed in this cell line (Fig. 
4.11C). Similarly, varying the concentration of imatinib used also led reduction in phospho-
MEK1/2 and phospho-ERK1/2 levels (Fig. 4.15B) due to degradation of MEK1 and MEK2 (Fig. 
4.11D). Collectively, our results demonstrate the ability of PAC-1, in combination with diverse 
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kinase inhibitors, to provide sustained inhibition of ERK1/2 and MEK1/2 phosphorylation, a result 
generally not observed in the combinations of these targeted kinase inhibitors with the MEK1/2 
inhibitor trametinib. 
 
Figure 4.15. Inhibition of MEK1/2 and ERK1/2 phosphorylation in K-562 (BCR-ABL) cells. (A) K-562 cells treated 
with PAC-1 + ceritinib for 48 hours led to sustained inhibition of MEK1/2 and ERK1/2 phosphorylation. Unlike the 
BRAFV600E, EGFRT790M, and EML4-ALK cells, activation of procaspase-3 was observed in cells treated with imatinib 
+ trametinib, leading to sustained inhibition of MEK1/2 and ERK1/2 phosphorylation. (B) At a lower concentration 
of imatinib (80 nM), the combination led to sustained inhibition of MEK1/2 and ERK1/2 phosphorylation. 
 
4.3. PAC-1 combinations delay acquired resistance in EGFRT790M and EML4-ALK NSCLC 
cells  
4.3.1. PAC-1 + osimertinib dramatically delay the onset of osimertinib resistance in 
EGFRT790M  cells 
Encouraged by effect of PAC-1 and vemurafenib in delaying resistance in BRAFV600E cells, 
the ability of the combination of PAC-1 and osimertinib to delay acquired resistance in EGFRT790M 
cells was investigated. In this case, H1975 and PC-9 GR cells were treated with indicated 
concentrations of PAC-1 and/or osimertinib for up to 28 days. In both cell lines, 8 days of single-
agent PAC-1 (2 μM) treatment had minimal cytotoxic effect compared to DMSO-treated samples. 
On the other hand, both single-agent osimertinib (30 nM) and the combination of PAC-1 and 
osimertinib were very effective inhibiting cell proliferation (Fig. 4.16). Following 28 days of drug 
treatment, resistant clones were clearly visible in PC-9 GR (Fig. 4.16A) and H1975 (Fig. 4.16B) 
cells treated only with osimertinib, in contrast to cells treated with both PAC-1 and osimertinib. 
108 
 
These results suggest that the combination of PAC-1 and osimertinib is effective in delaying the 
onset of osimertinib resistance in EGFRT790M cell lines.  
 
Figure 4.16. PAC-1 + osimertinib delayed resistance in (A) PC-9 GR cells and (B) H1975 cells following 28 days of 
treatment. Cells were fixed and stained with Sulforhodamine B (SRB) dye before imaging.  
 
Experiments were then conducted to compare the PAC-1 + osimertinib combination versus 
trametinib + osimertinib in delaying resistance in PC-9 GR cells. In this case, PAC-1 or trametinib 
(5 nM) as single agents had minimal cytotoxic effect as compared to DMSO-treated cells following 
8 days of treatment. As expected, treatment with osimertinib, PAC-1 + osimertinib, or trametinib 
+ osimertinib for 8 days was effective in inhibiting cell proliferation. Consistent with Fig. 4.16A, 
resistant clones were visible in PC-9 GR cells after 28 days of treatment with single-agent 
osimertinib but not in cells treated with PAC-1 and osimertinib (Figs. 4.17A and B). No resistant 
clones were also visible in cells treated with trametinib and osimertinib after 28 days. While there 
was a dramatic increase in the number of resistant clones present in cells treated with single-agent 
osimertinib after 35 days of treatment, no resistant clones were observable in cells treated with 
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either PAC-1 + osimertinib or trametinib + osimertinib (Figs. 4.17A and B). This observation 
suggests that the combination of PAC-1 + osimertinib is equipotent, but not, more efficacious in 
delaying resistance as trametinib + osimertinib.  
 
Figure 4.17. PAC-1 + osimertinib substantially delay or eliminate acquired resistance. (A) PC-9 GR cells were treated 
with indicated concentrations of PAC-1, osimertinib, trametinib, or the respective combinations for up to 35 days. 
Cells were fixed and stained with SRB dye before imaging. (B) Quantification of (A) by dissolving SRB dye in 10 
mM Tris (pH >10.4) and its absorbance measured at 510 nm. Data reported is the mean and standard error of two 
independent experiments.  
 
4.3.2. PAC-1 + ceritinib dramatically delay onset of ceritinib resistance in H3122 cells 
Finally, the ability of PAC-1 + ceritinib to delay acquired resistance in EML4-ALK cells 
was investigated. Here, H3122 cells were treated with indicated concentrations of PAC-1, 
trametinib, ceritinib, or the respective combinations for up to 32 days. Single-agent PAC-1 (2 μM) 
or trametinib (5 nM) treatment had minimal cytotoxic effect compared to DMSO-treated samples 
after 8 days of treatment. As expected, treatment with ceritinib, PAC-1 + ceritinib, or trametinib + 
ceritinib for 8 days was effective in inhibiting cell proliferation. (Fig. 4.18A). Resistant clones 
were visible in H3122 cells after 20 days of treatment with single-agent ceritinib but not in cells 
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treated with either PAC-1 and osimertinib or trametinib and ceritinib (Fig. 4.18A). After 32 days 
of treatment, there was a dramatic increase in the number of resistant clones present in cells treated 
with single-agent ceritinib but few resistant clones were observable in cells treated with PAC-1 + 
ceritinib (Fig. 4.18A). In cells treated with trametinib + ceritinib, small number of resistant clones 
were clearly visible, indicating the presence of ALKi + MEKi resistant H3122 cells (Figs. 4.18A 
and B).  
 
Figure 4.18. PAC-1 + ceritinib substantially delay or eliminate acquired resistance. (A) H3122 cells were treated with 
indicated concentrations of PAC-1, ceritinib, trametinib, or the respective combinations for up to 32 days. Cells were 
fixed and stained with SRB dye before imaging. (B) Zoom in view of H3122 cells treated PAC-1 + ceritinib, or 
trametinib + ceritinib for 32 days. Visibly more resistant colonies were seen in cells treated to trametinib + ceritinib 
compared to PAC-1 + ceritinib. 
 
In summary, the combination of kinase inhibitors targeting BRAFV600E, EGFRT790M, 
EML4-ALK, and BCR-ABL with PAC-1, leads to enhanced procaspase-3 activation and 
degradation of MEK1 and MEK2 kinases (Fig. 4.19). The degradation of MEK kinases then 
leads to sustained inhibition of MEK1/2 and ERK1/2 signaling. The combined effect of 
increased apoptotic cell death and sustained inhibition of the MAPK pathway that is observed in 
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the PAC-1 combination therapies work in tandem to dramatically delay or eliminate resistance.
 
Figure 4.19. Proposed mechanism of action of PAC-1 combination therapy with clinically approved kinase inhibitors 
examined in this work. Of critical importance is the ability of PAC-1 co-treatment to induce cleavage and thus 
sustained inhibition of MEK1 and MEK2 kinases, in contrast to the transient MEK inhibition afforded by trametinib. 
 
4.4. Discussion and outlook 
Significant progress has been made in understanding the mechanisms of acquired 
resistance to targeted kinase inhibitors. This understanding has translated into combination 
therapies for BRAFV600E melanomas and next-generation inhibitors for mutant EGFR and fusion 
EML4-ALK and BCR-ABL kinases. Unfortunately, cancer cells rapidly circumvent inhibition by 
these next-generation inhibitors via alternative resistance mechanisms, necessitating the 
development of newer drugs to combat resistant tumors. Moreover, a large proportion of drug-
induced resistance remains unexplained, meaning that newer drugs only benefit a small population 
of patients with molecularly defined resistance mechanisms.  
Our results show that co-treatment of a selective procaspase-3 activator, PAC-1, with 
diverse targeted kinase inhibitors is broadly effective in enhancing caspase-3 activity and apoptotic 
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cell death across diverse tumor histologies and driver mutations. The resultant caspase-3 activity 
led to enzymatic degradation of both MEK1 and MEK2 kinases and sustained inhibition of both 
MEK1/2 and ERK1/2 phosphorylation. While sustained ERK1/2 inhibition can be achieved with 
MEK1/2 inhibitors, this disrupts the negative feedback on RAF kinases, leading to the paradoxical 
hyper-phosphorylation of MEK1/2. Trametinib was developed as a “feedback buster” to minimize 
MEK1/2 hyper-phosphorylation46,47 but the inhibitory effect is relatively transient as shown 
literature39 and consistent with our results (Figs. 4.13 and 4.14). In contrast, we now show that 
caspase-3 mediated degradation of MEK1 and MEK2 kinases is an excellent strategy to inactivate 
ERK1/2, without the corresponding rebound in MEK1/2 phosphorylation. Due to the critical role 
of MEK1/2 kinases in regulating the MAPK pathway48, its sustained inhibition can be 
advantageous in further delaying the onset of acquired resistance.  
In contrast to direct procaspase-3 activation using PAC-1, non-specific induction of 
apoptosis using general cytotoxins such as doxorubicin can lead to hyper-activation of ERK1/2 
due to the cellular stress induced by these agents49,50. This observation underscores the importance 
of using a selective procaspase-3 activator instead of general cytotoxins, in combination with 
targeted kinase inhibitors, to avoid the paradoxical reactivation of ERK1/2 phosphorylation.  
Our results also show that addition of 1–2 μM of PAC-1 (a concentration easily achieved 
in human patients51) is effective in delaying acquired resistance to osimertinib and ceritinib in 
EGFRT790M and EML4-ALK NSCLCs respectively. Moreover, there is a marked benefit of 
combining PAC-1 with targeted kinase inhibitors as compared to MEK1/2 inhibition (with 
trametinib) in combination with targeted kinase inhibitors, in dramatically delaying or eliminating 
resistance. Two mechanisms are likely in play to account for this observation. First, enhanced 
apoptosis observed in cells treated with PAC-1 combination therapies likely impedes the 
emergence of resistant clones, as the vast majority of cancer cells are killed. Second, sustained 
MEK1/2 and ERK1/2 inhibition severely compromise the cells’ ability to proliferate and form 
resistant colonies.  
Targeted kinase inhibitors have had a dramatic impact on cancer treatment, but resistance 
has seriously limited the durability of this effect. Instead of developing new drugs for each 
resistance mechanism, in this work we have identified a potentially generalizable strategy to 
eliminate or substantially delay the resistance to targeted anticancer therapies, and have 
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successfully demonstrated its efficacy in cancers driven by BRAFV600E, EGFRT790M, and EML4-
ALK kinases. Given that PAC-1 is currently in a Phase I clinical trial (NCT02355535), and the 
kinase inhibitors used in this study are already approved by the FDA, the preclinical data results 
presented herein can inform the design of future trials to investigate novel combination therapies 
that may result in delayed or eliminated resistance.  
 
4.5. Materials and methods 
Cell lines and reagents 
K-562 (CRL-243) were obtained from ATCC. PC-9 GR, H1975, and H3122 were provided 
by Prof. Eric Haura (Moffitt Cancer Center). PC-9 GR, H1975, and H3122 were cultured in RPMI 
supplemented with 10% FBS (Gemini). K-562 was cultured in IMDM + 10% FBS. Osimertinib, 
trametinib, imatinib, and ceritinib were obtained from MedChem Express; gefitinib and Ac-
DEVD-AFC were obtained from Cayman chemicals. Annexin V-FITC (10040-02) was purchased 
from Southern Biotechnology. The following antibodies were purchased from Cell Signaling 
Technology: anti-PARP-1 (9532), anti-caspase-3 (9662), HRP-conjugated anti-β-actin (4967), 
anti-phospho-ERK1/2 (Thr202/Tyr204) (4370), anti-ERK1/2 (4695), anti-phospho-MEK1/2 
(9121), anti-MEK1 (9146), anti-MEK2 (9147) and HRP linked anti-rabbit IgG (7074). PAC-1 was 
synthesized as reported previously.52 
Cell line authentication 
All human cell lines used in this study (PC-9 GR, H1975, K-562, and H3122) have been 
authenticated using the PowerPlex16HS Assay (Promega) as described previously41: 15 
Autosomal Loci, X/Y at the University of Arizona Genetics Core.  
Cell viability assay 
1000 cells were seeded per well in a 96-well plate and allowed to adhere before DMSO 
solutions of osimertinib, gefitinib, or PAC-1 were added to each well. Final concentration of 
DMSO in each well is 0.5%. Compounds were incubated for 5 days and viability was assessed by 





Caspase-3/-7 activity assay 
For the EGFR T790M cell lines, 4,000 cells were seeded in each well of 96-well plates and 
allowed to adhere overnight. The next day, indicated concentrations of PAC-1 or osimertinib, were 
added and treated for 0, 2, 4, 24, 30, 35, 44 and 48 hour. K-562 cells were seeded at 3,000 cells 
per well and treated with indicated concentrations of PAC-1 or imatinib for 0, 2, 4, 24, 48, 68, and 
72 hour. H3122 cells were seeded at 4,000 cells per well and allowed to adhere overnight. The 
cells were then treated with indicated concentrations of PAC-1 or ceritinib for 0, 2, 4, 24, 44, and 
48 hour. 10 μM raptinal was used as the positive control throughout the experiment. After indicated 
incubation times, the cells were lysed and caspase-3/-7 activity was assessed via addition of 
bifunctional lysis and activity buffer (200 mM HEPES, 400 mM NaCl, 40 mM DTT, 0.4 mM 
EDTA, 1% Triton-X, pH 7.4) with 50 μM of fluorogenic Ac-DEVD-AFC substrate (λex=405 nm, 
λem=505 nm). Plates were pre-incubated at 37
oC for 30 minutes in the SpectraMax (Molecular 
Devices) plate reader and then read for 30 minutes at 3-minute intervals. Slopes for each well were 
calculated and averaged over six technical replicates. Activity is normalized to the maximal and 
minimal activity observed within the assay.  
Assessment of apoptosis by flow cytometry 
For the EGFRT790M cell lines, 40,000 cells were seeded in 12-well plates and allowed to 
adhere overnight. The next day, indicated concentrations of PAC-1 or osimertinib were added and 
allowed to incubate at 37oC for 48 hours. K-562 cells were seeded at 30,000 and incubated with 
PAC-1 or imatinib for 72 hours. In 12-well plates, 40,000 H3122 cells were seeded and allowed 
to adhere overnight. The next day, they were incubated with PAC-1 or ceritinib for 48 hours. After 
the indicated incubation period, cells were harvested and resuspended in 450 μL of cold buffer (10 
mM HEPES, 140 mM NaCl, 2.5 mM CaCl2, pH 7.4) premixed with Annexin V-FITC and PI dyes. 
Samples were analyzed on a BD Biosciences LSRII flow cytometer, and data analysis was 
performed using FSC Express Version4. 
Immunoblotting 
Cells were lysed using RIPA buffer containing phosphatase and protease inhibitor cocktail 
(Calbiochem). Protein concentration was determined using the BCA assay (Pierce). Cell lysates 
containing 8-20 g of protein were loaded into each lane of 4-20% gradient gels (BioRad) and ran 
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for SDS-PAGE. Proteins were transferred onto PDVF membrane (Millipore) for Western blot 
analysis.  
Long term experiments with EGFRT790M cell lines 
In 12 well plates, PC-9 GR or H1975 cells were seeded at 2,000 cells per well and allowed 
to adhere overnight. The next day, cells were treated with indicated concentrations of PAC-1 or 
osimertinib for 8 or 28 days. Media was refreshed every 3-4 days with new compounds.  
For experiments comparing the effect of PAC-1 combination versus trametinib combination, PC-
9 GR cells were seeded at 10,000 cells per well in 6 well plates and allowed to adhere overnight. 
The next day, cells were treated with indicated concentrations of PAC-1, osimertinib, or 5 nM 
trametinib for 8, 28, or 35 days. Media was refreshed every 3-4 days with new compounds. At the 
end of the incubation period, cells were fixed 10% trichloroacetic acid, stained with SRB, imaged 
using GelDox XR, and absorbance at 510 nm read using SpectraMax Plus plate reader.  
Long term experiments with EML4-ALK cell line 
H3122 cells were seeded at 10,000 cells per well in 6 well plates and allowed to adhere overnight. 
The next day, cells were treated with indicated concentrations of PAC-1, osimertinib, or 5 nM 
trametinib for 8, 20, or 32 days. Media was refreshed every 3-4 days with new compounds. At the 
end of the incubation period, cells were fixed 10% trichloroacetic acid, stained with SRB, imaged 
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